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Abstract 
 
 
Resveratrol (RV), a polyphenolic compound found in grapes and berries, has been 
shown to exert various health-beneficial effects that may help to prevent cardiovascular 
diseases and cancer. In atherosclerosis, vascular smooth muscle cells (VSMC) play a 
crucial role in most steps of disease progression. Upon growth factor attraction, VSMC 
start to migrate towards the site of blood vessel injury, start to proliferate and therefore 
contribute to the narrowing of the artery. Until now, the molecular mechanisms of the 
putative vasoprotective properties of RV are insufficiently understood. In this study, we 
therefore tried to unravel some of the molecular actions of RV in growth factor-activated 
VSMC. 
 By using epidermal growth factor (EGF) as activating stimulus we found that 
binding of RV to integrins, which play a mayor role in cell adhesion and survival, 
accounted only to a minor extend for the strong inhibiting properties of RV on Akt 
phosphorylation shown previously. EGF-mediated dephosphorylation of focal adhesion 
kinase (FAK), a key protein in processing integrin and growth factor signals, was 
completely restored by RV, which was mainly due to impaired binding of FAK to the 
phosphatase Shp-2. Moreover, single phosphorylation sites within FAK were very 
differently regulated by stimulation with EGF and RV. We furthermore excluded a major 
contribution of the estrogen receptor α (ERα) to EGF-mediated VSMC activation and 
were able to show that RV acted as a potent antagonist of ER in estrogen-stimulated 
cells. Extracellularly produced H2O2 was strongly affected by RV. Both, Angiotensin II- 
and EGF-induced production of extracellular H2O2 were completely blocked. Additionally, 
unexpected high basal levels of H2O2 in unstimulated VSMC were diminished by 60% 
underlining RVs very potent antioxidative properties. Migration studies illustrated that RV 
was able to selectively abrogate EGF- but not PDGF-triggered chemotaxis of VSMC. 
Long-term treatment with the growth factors revealed that enhanced FAK 
phosphorylation was not affected by RV. By conducting cytoskeleton staining 
experiments, we could observe that especially lamellipodia formation was impaired in 
EGF-, but not PDGF-stimulated cells pretreated with RV. The molecular basis for this 
phenotypic limitation could be specifically attributed to the small GTPase Rac1. Pull-
down experiments revealed that Rac1 activity of EGF- but not PDGF-stimulated VSMC 
was strongly inhibited by additional treatment with RV, whereas activity of cdc42 was not 
changed.  
 In summary, our study contributes new knowledge to understand the molecular 
mechanisms by which RV interferes with signalling pathways induced by growth factors 
in vascular smooth muscle cells. Moreover, we could identify a novel anti-migratory 
effect of RV on EGF-stimulated VSMC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zusammenfassung 
 
 
Dem polyphenolischen Molekül Resveratrol (RV), das vor allem in Trauben und 
Beerenfrüchten vorkommt, werden präventive Wirkungen bei Herzkreislauf-
Erkrankungen und Krebs zugeschrieben. Vaskuläre glatte Muskelzellen (VSMC) spielen 
bei der Entstehung von Arteriosklerose eine entscheidende Rolle. Durch Ausschüttung 
von Wachstumsfaktoren wandern VSMC in Richtung der Intima und beginnen sich dort 
zu teilen, was zur Verengung des Blutgefäßes beiträgt. Bis heute sind die molekularen 
kardiovasoprotektiven Mechanismen von RV ungenügend verstanden. Aus diesem 
Grund versuchten wir in dieser Studie mögliche molekulare Mechanismen von RV 
aufzuklären.  
 In mit epidermal growth factor (EGF) stimulierten VSMC konnten wir zeigen, 
dass das Binden von RV an Integrine, welche wichtige Funktionen für das Anhaften und 
das Überleben der Zelle übernehmen, nur einen geringen Anteil an der stark 
inhibierenden Wirkung von RV auf die Phosphorylierung von Akt, welche bereits früher 
von unserer Arbeitsgruppe gezeigt wurde, hat. Die EGF-induzierte Dephosphorylierung 
von focal adhesion kinase (FAK), die ein zentrales Protein bei der Integrin-, und 
Wachstumsfaktor-vermittelten Reizweiterleitung ist, wurde durch RV-Behandlung 
vollständig verhindert. Dies war auf eine verminderte Bindung von FAK an die 
Phosphatase Shp-2 zurückzuführen. Zudem waren einzelne Phosphorylierungsstellen 
innerhalb von FAK durch EGF-, und RV-Behandlung sehr unterschiedlich reguliert. Eine 
Beteiligung des Östrogenrezeptors α (ERα) an der EGF-vermittelten Aktivierung von 
VSMC konnten wir ausschließen, obwohl RV eine antagonistische Wirkung auf ER in 
Östrogen-stimulierten VSMC zeigte. Extrazellulär produziertes H2O2 war sehr stark von 
RV beeinflusst. Sowohl die Angiotensin II-, als auch die EGF-induzierte H2O2-Produktion 
wurden durch Vorinkubation mit RV inhibiert. Darüber hinaus konnten wir beobachten, 
dass die unerwartet hohen basalen H2O2-Werte von RV zu 60% inhibiert werden 
konnten, was die stark antioxidative Wirkung von RV unterstreicht. Migrations-Studien 
zeigten uns, dass RV selektiv EGF-, aber nicht platelet-derived growth factor (PDGF)-
vermittelte Migration vermindern konnte. Langzeit-Stimulation mit den 
Wachstumsfaktoren zeigte, dass die erhöhte FAK-Phosphorylierung durch 
Vorinkubation mit RV nicht verändert war. Durch das Färben des Cytoskeletts von 
VSMC zeigte sich, dass die EGF-induzierte aber nicht die PDGF-vermittelte Formierung 
von Lamellipodien durch RV stark beeinflusst war. Auf molekularer Ebene konnte die 
kleine GTPase Rac1 als Grund für die verminderte Lamellipodien-Ausbildung ausfindig 
gemacht werden. Präzipitations-Experimente zeigten, dass die Aktivität von Rac1 
ausschließlich in EGF-stimulierten jedoch nicht in PDGF-behandelten VSMC durch RV 
inhibiert wurde. Die Aktivität von cdc42 hingegen wurde durch keinen Stimulus 
beeinflusst.  
 Zusammengefasst können wir sagen, dass diese Studie dazu beiträgt, die 
molekularen Mechanismen von RV in Wachstumsfaktor-induzierten VSMC besser zu 
verstehen. Zusätzlich konnten wir einen neuartigen anti-migratorischen Effekt von RV in 
EGF-stimulierten VSMC identifizieren. 
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B  Introduction 
 
 
 
1. The cardiovascular system 
 
 
In vertebrates, supplementation and distribution of nutrients, oxygen and collection of 
waste products is carried out by a closed circulating system, which comprises a pump 
(the heart), a distribution network (the blood vessels) and liquid (the blood itself), which 
is titled “the cardiovascular system” [1]. Diseases connected to the cardiovascular 
system include stenosis of blood vessels (atherosclerosis, coronary heart disease 
[CHD]), heart-associated diseases (heart failure) and systemic diseases, which often 
arise from aforementioned maladies (hypertension, arrhythmia, stroke, heart attack) [2]. 
The risk factors to develop a cardiovascular disease (CVD) are as manifold as the 
resulting illnesses and include: smoking, high cholesterol diet, minor physical exercise 
and genetic predisposition [3, 4]. The world-wide frequency of CVD rose steadily over 
the last decades. In the U.S., over one-third of the population suffers from one or more 
diseases concerning the cardiovascular system and therefore such illnesses are 
nowadays the major cause of death, followed by cancer. The resulting direct and indirect 
costs for 2009 will exceed 475 Billions of Dollars in the U.S. [5]. Therefore, huge effort is 
made all over the world to cope with and effectively combat various CVD.  
 
The human blood vessel consists of three distinct layers, each separated from the other 
by an elastic lamina. The intima is the most inner and thinnest region consisting of one 
single layer of endothelial cells, which forms the barrier to the circulating blood stream. 
The intima is surrounded by the media, the thickest layer within the vessel, mainly built 
up by vascular smooth muscle cells (VSMC) and connective tissue. VSMC within the 
media are mainly responsible for constriction and dilatation of the blood vessel. The very 
outside region is the adventitia, which consists almost exclusively of connective tissue 
and which is strongly innervated to supply the blood vessel with neuronal inputs [1].   
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1.1. Molecular events of atherosclerosis 
 
Atherosclerosis, blood vessel narrowing in response to inflammation and lipid 
accumulation, is a multi-step process and involves diverse subtypes of cells and tissues 
[6]. Risk factors which might lead to atherosclerosis can be subsumed in two groups: 
genetic background and environmental factors. Whereas genetic predispositions include 
hypercholesterolaemia causing high levels of low-density lipoprotein (LDL) [7], reduced 
concentrations of high-density lipoprotein (HDL) [8], mutations in the gene encoding LDL 
receptor-related protein 6 (LRP6) [9], gender [10] and family history [11], environmental 
factors include high-fat diet, smoking [7], or infections [12]. In most cases, however, a 
combination of increased life span, unhealthy eating habits and genetic susceptibility 
lead to atherosclerosis or other types of CVD.  
 
The initial steps of atherosclerosis include the accumulation of LDL in the sub-
endothelial matrix, which often takes place at arterial branching points, where 
endothelial cells (EC) are exposed to enhanced fluid shear stress [13]. In these areas, 
the EC monolayer is not as tight as in tubular regions of arteries and therefore 
lipoproteins can diffuse through the endothelium [14]. Together with LDL, other 
lipoproteins as lipoprotein A accumulate in the intima of the vessels and activate EC to 
produce pro-inflammatory molecules, as macrophage-stimulating growth factor (M-CSF) 
[15]. By upregulating adhesion molecules on their surface, EC attract monocytes and 
lymphocytes to bind and “roll” along the endothelial monolayer until they migrate into the 
intima of the vessel to become macrophages (Fig. 1). To be taken up by invading 
macrophages, LDL has to be highly oxidized, which is triggered by reactive oxygen 
species (ROS) and the activity of different enzymes, such as myeloperoxidase, 
sphingolipase and 12/15-lipoxigenase [16, 17]. In general, macrophages play a pivotal 
role in many stages of atherosclerosis from the initiation to more progressive states and 
exert many effects within the lesion, like infiltration, LDL uptake and cytokine production 
[18]. Macrophages express toll-like receptors (TLR) which have been shown to act as 
receptors for heat-shock proteins and modified lipids and lead to enhanced macrophage 
activation upon binding of their ligands [19]. On the other hand, macrophages 
upregulate a set of scavenger receptors as CD36 (cluster of differentiation 36) or 
scavenger receptor-A (SR-A), which enables them to bind oxidized LDL to become foam 
cells [20].  
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Figure 1: Four main steps in 
the progression of athero-
sclerosis 
Atherogenic factors lead to 
endothelial dysfunction which, in 
turn, results in the upregulation 
of adhesion molecules. Immune 
cells (predominantly monocytes 
and T-cells) bind to receptors on 
endothelial cells and invade the 
intima of the vessel. Upon 
oxidative stress, LDL becomes 
oxidized and is subsequently 
taken up by macrophages which 
develop into foam cells. 
Enhanced growth factor 
production leads to the attraction 
and proliferation of VSMC which 
can result in the formation of a 
fibrotic cap. Cap rupture can 
happen in response to enzymatic 
activity, apoptosis of VSMC and 
shear stress and is followed by 
thrombosis. Sophisticated 
lesions can calicify and therefore 
prevent further fibrotic events. 
For abbreviations, see section G. 
Figure from Dzau et al. 2002. 
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A recent study revealed that the interaction of CD40 with CD40L, which is a central 
event in the induction of immune responses in lymph nodes, is also taking place in the 
atherosclerotic lesion. Since CD40 is expressed on macrophages, the interaction 
between T-cells and macrophages contributes to enhanced cytokine production [21]. 
High growth factor concentrations within the area of the lesion finally leads to the 
attraction of VSMC which migrate from the media into the intima of the vessel [22].  
 
As a next step, VSMC start to proliferate and to produce a tight meshwork of 
extracellular matrix (ECM) which leads to both the thickening of the lesion and the 
building of a new layer of cells within the atherosclerotic plaque, the neointima [23]. 
VSMC then start to produce growth factors, such as epidermal growth factor (EGF), 
platelet-derived growth factor (PDGF) or Angiotensin II (Ang II) which act both in an 
autocrine and paracrine way. It is still a matter of debate, whether neointima formation 
arises from some few VSMC, which expand in a clonal fashion, or if there is steady-state 
transmigration from the media into the atherosclerotic lesion [24, 25]. Furthermore, there 
is evidence that EC are able to trans-differentiate into VSMC in stages during 
embryogenesis and additionally give rise to neointima formation [26]. Some studies 
highlighted that bone marrow-derived progenitor cells of VSMC can account for the 
overall pool of VSMC within neointimal regions [27]. 
 
Highly proliferative VSMC produce an augmented mass of ECM, and together with 
cholesterol and its esters a fibrous cap can develop (Fig. 1). The incidence of fibrous 
lesions is enhanced by some parameters like hypertension or elevated homocysteine 
levels [28]. In response to shear stress and/or activity of certain enzymes within the 
lesion, such as matrix metalloproteinases (MMP) and collagenases, the fibrous cap can 
rupture [29, 30]. Furthermore, necrotic and apoptotic cells in the lesion can enhance 
rupture events, too [31]. Since the rupture of the cap directly leads to platelet 
aggregation at the site of injury, obviation of thrombosis is an important field of today´s 
research. Atherosclerosis-mediated thrombosis accounts for the highest number of 
atherosclerosis-related deaths due to stroke or heart attack. There are, however, some 
scientific problems to cope with, since no reliable and widely accepted animal models for 
atherosclerosis-associated thrombosis exist [32]. Calcification and neovascularization on 
the other hand are able to counteract thrombus origination, since both phenomena often 
lead to the stabilisation of the fibrous caps [33].  
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1.2. The role of VSMC in atherosclerosis 
 
As already discussed above, VSMC play a crucial role in many stages of atherosclerosis 
[22], whereas their most predominant impact is considered to be on more advanced 
stages of the disease. However, VSMC can be found in the pre-atherosclerotic intima as 
well, where they build up so-called “intimal thickenings”. They are predominantly found 
in regions of arterial branches and occur nearly in all infants and can even develop by 
age [34]. Moreover, studies revealed that arterial regions which are likely to develop 
atherosclerotic lesions contain more intimal VSMC as other zones of the blood vessels 
[35]. Like in the research field of thrombosis, there is still a lack of appropriate animal 
models in the scientific research area of intimal thickenings.  
 
The phenotype of intimal VSMC clearly differs from those of the media. In comparison to 
medial VSMC, intimal VSMC have a higher capacity to produce ECM and cytokines, 
whereas they express lower amounts of α-smooth muscle actin and smooth muscle 
myosin heavy chain (SM-MHC) [36]. Additionally, several studies have pointed out that 
VSMC are able to undergo switches from a contractile to a more “synthetic” phenotype, 
which is characterized by a higher ability to migrate and to take up lipids. Therefore 
VSMC give rise to the pool of lipid-loaded cells within the lesion [37]. Intercellular 
adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) are 
well studied transmembrane proteins predominantly found on endothelial cells, where 
they are responsible for the binding and “rolling” of monocytes and leukocytes along the 
EC monolayer. The existence of VCAM-1 on VSMC opens new perspectives for cell-cell 
interactions in atherosclerotic lesions, as it was reported that VSMC could directly 
interact with both, macrophages and T-cells and therefore contribute to the inflammatory 
reaction within lesions [38]. VCAM-1-mediated interaction of VSMC with macrophages 
even prevented the latter from apoptosis, which might account for monocyte 
accumulation during early stages of atherosclerosis [39].  
 
Cytokines are produced by nearly all cell types found in atherosclerotic lesions. VSMC 
predominantly release PDGF, interferon gamma (IFNγ), monocyte chemoattractant 
protein-1 (MCP-1) and transforming growth factor beta (TGF-β). The contribution of 
VSMC-produced cytokines to the entire cytokine pool in the lesions is not exactly known, 
since all aforementioned molecules can be supplied by other cell types as well [40]. A 
INTRODUCTION 
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key event during atherosclerosis involving VSMC is the production of ECM. The network 
consists of proteoglycans, fibronectin and type I collagen. Moreover, lipoprotein 
integration into the meshwork is one hallmark of atherosclerotic ECM [41]. Once 
integrated, LDL becomes more rapidly oxidized which in turn enhances proteoglycan 
production of VSMC resulting in a positive feedback loop accelerating lesion progression 
[42]. The composition of the ECM has furthermore influence on VSMC proliferation, 
since laminin- or collagen-bound VSMC predominantly found in healthy vessels are 
arrested in G1 phase, whereas proteoglycan-bound smooth muscle cells re-enter the cell 
cycle by downregulation of inhibitors of cyclin-dependent kinases (CDK) [43].  
 
Hypertrophy is a unique feature of muscle cells and contributes to the disease pattern of 
hypertension and atherosclerosis [44]. It is defined as an increase in cell size without 
duplication of DNA and is a reversible process which plays an important role in arterial 
wall thickening [45, 46]. The main molecules to induce hypertrophy are ligands of G 
protein-coupled receptors (GPCR), such as Ang II, the major effector of the renin-
angiotensin system (RAS), which is highly involved in a plethora of CVD. It acts mainly 
in an autocrine fashion to induce protein synthesis, ROS production and water uptake 
[47], which will be discussed later in detail.  
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2. VSMC activation 
 
 
2.1. Activation by EGF 
 
One of the most abundant receptors found on cells contributing to atherosclerosis is the 
EGF receptor (EGFR). It is part of the receptor tyrosine kinase (RTK) family and has 
been detected on rat and human VSMC [48, 49], endothelial cells and macrophages [50]. 
Moreover, EGFR overexpression is often an incidence for the development of solid 
tumours [51]. The receptor is contributing to different stages of mammalian embryonic 
development and EGFR knock-out mice display epithelial immaturity and dysfunction 
and die 15-18 days after birth [52, 53].  
 
EGFR ligands are small peptides sharing a motif of six cysteine residues within a region 
of 35-40 amino acids, which build up a three-loop structure to bind to their cognate 
receptors. The family consists of: EGF, heparin-binding EGF-like growth factor (HB-
EGF), TGF-β, epiregulin (EPR), betacellulin (BTC), amphiregulin (AR) and four 
neuregulins (NRG-1-4) [54]. To become biologically active, all members of the family 
have to be cleaved by a disintegrin and metalloproteinase (ADAM) proteins. The inactive 
precursor is a transmembrane protein which contains nine extracellular domains of 
which only the membrane-closest is defined as the later active molecule [55]. Whereas 
EGF is only secreted by platelets in sufficient amounts, HB-EGF can act both autocrine 
and paracrine and is released by nearly all cells located at atherosclerotic lesions. 
Moreover, it has become recognized that HB-EGF is elevated in adipose tissue, and 
obese mice and humans show increased plasma levels of HB-EGF, which may give rise 
to coronary diseases [56]. Nevertheless, all members of EGFR ligands trigger 
transformation of VSMC to a migratory and proliferative phenotype and are involved in 
the progression of atherosclerosis [57]. Since platelets are not able to synthesize EGF 
on their own, it is speculated that EGF is produced by megakaryocytes and stored by 
platelets in high amounts for later growth factor release [58]. 
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The 200 kbp gene encoding for the EGFR protein is located on the short arm of 
chromosome 7 and gives rise to four members of the protein family (named ErbB1-4) 
[59]. Whereas VSMC express all four types of EGF receptors, other cells involved in 
atherosclerosis only display ErbB1 (also termed as the “classical” EGFR) on their 
surfaces. In addition, binding specificities underline the importance of ErbB1, since it is 
the only receptor type to bind EGF, HB-EGF, TGF-β, EPR and BTC [60]. The receptor 
comprises a 621 amino acid extracellular, a 23 amino acid transmembrane and a 542 
amino acid cytoplasmatic domain, whereas the extracellular region can be dissected into 
four subdomains. Two cysteine-rich domains are interacting with two identical domains 
of other EGFR proteins to build homo- or heterodimers, whereas the two remaining 
domains interact with the ligand and thus account for the specificity of the receptor [61]. 
The most conserved region within the EGFR protein family encodes for the 
cytoplasmatic kinase domain which was reported not to affect the expression pattern or 
membrane trafficking of EGFR but is pivotal for signal transduction and cellular 
responses [62].  
 
The potency of a growth factor to induce a cellular response is not only determined by 
the concentration of the ligand, but also by the surface abundance of the receptor. 
Therefore receptor shuttling, internalization and degradation are appropriate means for 
cells to influence signalling strength and duration [63]. After protein translation, EGFR 
are directly shuttled to the membrane, where they can be integrated into caveolae 
(cholesterol-rich membrane regions with high amounts of the protein caveolin), which is, 
however still a matter of debate [64, 65]. Upon ligand binding EGFR are shuttled to lipid 
rafts, which are cholersterol-rich membrane regions where several proteins are 
concentrated and therefore reflect “hot spots” of signalling [66]. Moreover, it was 
observed that EGF stimulation leads to downregulation of EGFR on the surface, but it is 
still debated whether this fact is due to enhanced receptor endocytosis or a decrease in 
EGFR backhaul to the surface [63]. In addition, the dimerization status of the receptor is 
another variable in the internalization efficiency, since EGFR homodimers are more 
rapidly endocytosed as heterodimers of EGFR plus ErbB2 or ErbB3 [67].  
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The initial steps of EGFR-mediated signalling pathways are incompletely understood. 
Two current models exist: (a) one ligand-bound EGFR monomer binds asymmetrically to 
an unligated EGFR before a second EGF molecule binds [68]; (b) symmetric interaction 
of two EGFR monomers which are both already coupled to EGF molecules [69]. 
However, receptor dimerization is the crucial step to bring the two cytoplasmatic kinase 
domains in proximity to stabilize and autophosphorylate each other at the very C-
terminal region. This part of the receptor is the most variable within the receptor family 
and contains five important phosphorylation-sensitive tyrosine residues, which can be 
both autophosphorylated and transphosphorylated, for example by Src [70, 71]. 
Thereafter, src homology 2 (SH2) domain-containing proteins can bind and initiate the 
assembly of signalling complexes. Among others, direct interaction partners of EGFR at 
distinct tyrosine residues at the C-terminus are: phospholipase C gamma  (PLCγ), 
phospholipase D (PLD), Src, growth factor receptor-bound protein 2 (GRB2), GRB2-
associated binder-1 (Gab-1), , SH2-containing phosphatase-1 (Shp-1) and Ras [66, 72-
74]. The fact that various EGFR homo- and heterodimers can emerge potentiates the 
number of possible C-terminal signalling complexes and is therefore an important basis 
for the diversity of the signalling output [75]. Phosphoinositide-3 kinase (PI-3K), for 
example was shown to interact either in direct fashion or indirectly via adapter proteins, 
depending on the type of the EGFR dimer [76]. Additionally, Xia and colleagues have 
shown that signal transducer and activator of transcription (STAT) proteins were found 
in direct interaction with unphosphorylated EGFR, meaning that also inactive EGFR is 
able to bind proteins [77]. Given the fact that many signalling complexes can form as a 
result of EGFR activation, it is unsurprising that multiple pathways, which are often cross 
linked, are brought into action upon EGF stimulation. In the following section, only the 
most important cascades will be discussed.  
 
Raised attention has been drawn to the Ras activation pathway over the last decades. 
EGFR-mediated Ras activation starts with the recruitment of GRB2 (Fig. 2). It is still not 
fully clear if in this particular case, GRB2 binds directly to the activated EGFR or needs 
the assistance of the adapter SH2-containing collagen-related protein (Shc) [78]. 
Nevertheless, key player of Ras activation is GRB2, which is constitutively bound to the 
guanine nucleotide exchange factor son of sevenless (SOS). By bringing SOS in 
proximity to membrane-anchored Ras, GDP is exchanged for GTP leading to Ras 
activation. Next, Raf gets activated by the kinase domain of Ras. MAPK/ERK kinase-1 
INTRODUCTION 
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(MEK-1) is subsequently phosphorylated and finally activates ERK-1 and -2, which 
translocate to the nucleus where they phosphorylate specific transcription factors, as Ets 
or c-fos [79]. The activation of MAPK provides a negative feedback loop, since once 
phosphorylated, the GRB2-SOS complex dissociates and abrogates the signal cascade 
[80]. The adapter protein GRB2 consists of two SH2 domains and one SH3 domain and 
is therefore able to interact with a multitude of different proteins. In this respect, the 
question arises, how specificity and selectivity are achieved. First, compartmentalization 
plays an important role. In one small area of the cell, for example at the membrane, the 
concentration of certain proteins is higher than elsewhere. Second, the concentration of 
individual binding partners has impact on the protein-protein interactions. At low 
concentrations interactions of highly affine proteins are preferred, whereas low-affinity 
interactions can take place when protein concentrations are high. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: EGF-mediated signalling  
Upon ligand-binding, EGF -monomers form homo- or heterodimers to transphosphorylate their C-
terminal domains. Either adapter proteins (GRB2) or kinases (PI-3K) can bind and initiate signal 
transduction towards the Ras or the Akt pathway. For abbreviations, see section G. Figure from 
Sharma et al. 2007, adopted. 
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A second major interaction partner of great importance is Src, though it is not fully 
understood to which extent EGFR and Src need each other to be activated. On the one 
hand, overexpression of Src clearly enhanced proliferation of EGF-triggered cells, but 
contrariwise interaction of Src with the EGFR was difficult to prove. The two kinases 
share many substrate molecules making it impossible to distinguish between Src- and 
EGFR-mediated activation [81, 82]. Hence, it is controversial if Src accounts for EGFR 
activation or if Src activity is the result of an upstream EGFR activation.  
 
Another class of proteins activated by EGFR signalling is connected to phospholipid 
metabolism. Phospholipids often act as important second messengers in the cell and 
therefore their production has to be regulated in a stringent fashion [83]. Phosphatidic 
acid (PA) is generated by PLD from phosphatidylcholine and PLD can be directly 
activated by the EGFR [84]. PLCγ on the other hand catalyzes 1,2-diacylglycerol (DAG) 
plus 1,3,5-trisphosphate (IP3) from its precursor phosphatidylinositol 4,5-bisphosphate 
(PIP2). DAG is an important cofactor for protein kinase C (PKC) and IP3 triggers Ca2+ 
release from intracellular stores and thus affects Ca2+-dependent signalling pathways 
[85]. By affecting survival, proliferation and migration PI-3K is inevitable in intracellular 
signal responses [86]. PI-3K is a heterodimer consisting of a regulatory domain (p85) 
and a catalytic subunit (p110). Of the three family members only class IA-enzymes of PI-
3K are activated by the EGFR [87]. In the cytoplasm, p110 remains in an inactive state 
tightly bound to p85. By binding directly or via adapter proteins to EGFR, p85´s function 
is to bring p110 in vicinity to its membrane-anchored substrate PIP2 where PI-3K 
changes its conformation and p110 becomes activated (Fig. 2) [88]. PI-3K catalyzes the 
production of membrane-bound PIP3 from PIP2 which serves as docking site for 
pleckstrin homology domain (PH)-containing molecules.  
 
One of the best characterized PIP3-binding molecules is Akt (also named protein kinase 
B [PKB]). Akt signalling plays a pivotal role in cell survival and cell cycle events. It was 
first detected as a homologue of viral v-akt and was shown to display protein homology 
with protein kinase A and C (PKA, PKC) leading to its surrogate name PKB [89, 90]. 
Until today, three members of the Akt family have been described (Akt1-3). Although 
they are transcribed from different genes, they share high sequence similarity and 
consist of an N-terminal PH domain followed by a kinase domain and a C-terminal 
regulatory domain [91]. Akt1 and Akt2 display a broad tissue distribution pattern, 
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whereas Akt3 is predominantly found in neuronal cells [92]. In vascular tissues, Akt1 has 
a central role [93]. Two phosphorylation sites are crucial for activation of Akt: Thr308 and 
Ser473, whereas the latter amino acid is required for full kinase activity and might be 
autophosphorylated by Akt itself or by the mTOR complex 2 (mTORC2) [94]. As already 
mentioned above, by formation of PIP3 Akt is recruited to the membrane, where 3-
phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates Akt at Thr308 (Fig. 
2) [95]. Active Akt is then able to phosphorylate a broad spectrum of substrates, 
including prosurvival proteins and molecules promoting cell cycle progression, for 
example cAMP response element-binding protein (CREB), inhibitor of NF-κB (Iκ-B), 
p21WAF1 or endothelial nitric oxide synthase (eNOS). Furthermore it can inactivate 
proapoptotic molecules like BAD [96]. Akt is therefore a central molecule in EGF-
mediated VSMC activation.  
 
It has also been reported that the estrogen receptor (ER) is able to take part in EGFR 
signalling [97]. Truncated versions of ERα were shown to be located at the cell 
membrane within caveolae, where they collaborate with PI-3K and Src in signalling [98]. 
Furthermore, a potential contribution of ER to Akt signalling has been documented [97].  
 
 
2.2. Activation by PDGF 
 
As the EGFR, the platelet-derived growth factor receptor (PDGFR) is a member of the 
RTK family. The fully functional PDGFR is a dimeric molecule consisting of either two α-
two β- or one α- and one β-monomer(s) [99]. The PDGFR can be found on various cell 
types, including VSMC, endothelial cells, fibroblasts and neurons [100]. The great 
importance of the PDGFR has been demonstrated with the help of mouse knock-out 
studies, in which animals displayed severe kidney and blood vessel deficiencies and 
exhibited embryonic lethality [101]. The different cell types which contribute to 
atherosclerosis mainly express PDGFR-α and -β homodimers. The ligands for PDGFR 
appear in three isoforms, as do the receptors: PDGF-AA, PDGF-BB and PDGF-AB, 
each of them favouring its cognate receptor. PDGF-BB, however, has the ability to bind 
to all three receptor dimers and is therefore often used as the experimental stimulus of 
choice [102]. Platelet-released PDGF is a very potent chemoattractant and mitogenic 
molecule, whose binding to the receptor triggers similar intracellular signalling events as 
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EGF does at the EGFR and for VSMC, PDGF represents even the strongest pro-
migratory molecule. Dimerization of the PDGFR leads to autophosphorylation at several 
tyrosine residues within the 459 amino acids-containing C-terminus and subsequent 
binding of mainly SH2 domain-containing binding partners, among others: PI-3K, Src, 
PLCγ, Shp-2, GRB2, Ras and GTPase activating protein (GAP) [103]. By activation of 
the Ras, PI-3K and PKC pathways PDGF signalling leads to cell proliferation, enhanced 
motility and reduced apoptosis, while diverse pathways are able to cross-talk with each 
other. As in EGF signalling, PDGF-triggered cell activation is influenced by both, ligand 
concentration and receptor abundance [104]. Diverse negative feedback loops enable 
the shut-off of PDGF signalling, e.g. activation of certain phosphatases (Shp-2, low 
molecular weight phosphotyrosine phosphatase [LMW-PTP] or CD45), induction of 
cyclooxygenases or receptor internalization [105-107].  
 
Taken together, PDGF signalling has many molecular similarities with EGF signalling, 
since both stimuli lead to enhanced cell viability, motility and proliferation. Moreover, the 
same adapter proteins can be recruited to the activated receptors leading to the 
induction of aforementioned signalling pathways. Evident cell-specific differences 
between EGF and PDGF signalling are due to unequal receptor expression levels, 
ligand concentration and the duration of the signalling events [108].  
 
 
2.3. Activation by Ang II 
 
Ang II is the end product of a cleavage cascade involving several enzymes. 
Angiotensinogen, produced in the liver, is cleaved by renin to form angiotensin I (Ang I). 
By subsequent activation of angiotensin converting enzyme (ACE), Ang I is further 
cleaved to form the active octopeptide Ang II [109]. Since Ang II controls systemic blood 
circulation effects such as vasoconstriction or water and salt homeostasis, severe 
complications can occur if levels are enhanced. One of the most prominent negative 
effects is hypertension in response to enhanced and sustained vasoconstriction and 
therefore a lot of scientific effort is made to find accurate ways to counteract enhanced 
Ang II levels [110]. Until now, ACE inhibitors and Ang II type-1 receptor (AT-1R) 
antagonists are used to medicate hypertension [111]. 
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At the molecular level Ang II mainly acts via binding to AT-1R, a member of the seven-
transmembrane family of GPCR. GPCR represent the biggest family of transmembrane 
receptors in many species, including mouse and human [112]. They comprise seven 
transmembrane α-helices which covalently bind to G proteins at their C-terminal 
cytoplasmatic domain. The superfamily of G proteins can be divided into two classes. 
The first group of G proteins consists of only one subunit and these molecules are 
therefore called small GTPases. They will be discussed in another section later in detail. 
The other class of G proteins are heterotrimeric G proteins (also called large G proteins), 
which comprise three subunits (α, β, γ) and are coupled to GPCR. They are divided into 
four subclasses according to their α-subunit. Large G proteins get activated by ligand-
induced conformational changes of the receptor which in turn leads to the exchange of 
GDP for GTP and subsequent dissociation of the α-subunit from the βγ-subunit [113]. 
Both subunits act as second messengers and can separately activate different signalling 
pathways [114].  
 
AT-1R are expressed on a wide variety of cells, including vascular and coronary tissues 
[115]. The receptor expression can be influenced by Ang II itself, since enhanced Ang II 
levels can lead to upregulation of AT-1R [116]. Furthermore other agonists, as EGF or 
PDGF can influence AT-1R expression [117]. Like in the case of RTK, AT-1R signalling 
can be abrogated by receptor internalization after ligand binding. Another negative 
feedback loop is receptor phosphorylation by G protein receptor kinases (GRK), which 
leads to the release of the G protein from the receptor [118].  
 
Ang II signalling in VSMC leads to enhanced vasoconstriction, hypertrophy, proliferation 
and cell survival. G protein-triggered activation of signalling molecules include PLC and 
PLD, which produce second messengers such as DAG or IP3, in turn leading to Ca2+ 
efflux and cell contraction [119]. Moreover by activating PKC, DAG production leads to 
the activation of the growth-promoting Ras pathway [120]. Besides the “classical” G 
protein-mediated activation of signalling cascades, production of reactive oxygen 
species (ROS) plays an essential role in Ang II-triggered VSMC activation. ROS are 
mainly produced by NAD(P)H oxidases (NOX) and comprise several oxygen products 
including superoxide (O2-), hydroxyl radicals (OH-) and hydrogen peroxide (H2O2) [121]. 
Especially hydrogen peroxide and superoxide have emerged not to be only oxidizing 
agents but being important second messengers participating in diverse signalling 
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cascades [122]. In addition to p38 activation, ROS are able to trans-activate RTK like 
EGFR and PDGFR in different ways. At least three possible mechanisms have been 
unravelled: (a) cysteine-containing, oxidation-sensitive phosphatases, for example Shp-
2, are directly inhibited by ROS; (b) ROS can directly modify protein-protein interactions 
by altering the occurrence of disulfide bonds; (c) ROS enhance proteolysis of 
suppressor-proteins [123, 124]. All these actions prolong or even enhance RTK 
signalling cascades and therefore contribute to a more activated cell phenotype. 
 
In feedback regulation processes of signalling cascades, phosphatases in general and 
protein tyrosine phosphatases (PTP) in particular, act in a coordinated manner together 
with kinases to control both, strength and duration of signalling events in a very fine-
tuned manner [125]. For the last few years it has become more and more evident how 
important and complex the activation, action and interplay between kinases and 
phosphatases are. Shp-2 is a non-receptor PTP consisting of two SH2 domains and a 
catalytical domain [126]. Shp-2 can be held in a self-inactivating conformation, where 
one of the SH2 domains physically interacts with the catalytical phosphatase domain. 
Upon binding to either phosphorylated tyrosine residues within the C-terminal domain of 
Shp-2 itself or to phosphorylated tyrosine residues on other proteins, Shp-2 opens up its 
conformation and enables the catalytic domain [127]. Another distinctive property of PTP 
is the presence of an oxidation-sensitive cysteine residue within the catalytic domain, 
which can lead to reversible inhibition of the phosphatase in the presence of ROS [128]. 
This additional inhibitory effect of ROS on PTP activity can result in sustained signal 
durations and is therefore an important regulatory mechanism in several pathways [129]. 
Moreover, Shp-2 was shown to be influenced in growth factor signalling in both, VSMC 
and fibroblasts and is involved in cell migration [130-132].  
 
 
2.4. Activation via integrins 
 
Integrins are a huge family of transmembrane proteins which major functions are the 
anchorage of cells to the surrounding ECM, the intracellular fixation of the cytoskeleton 
and the transmission of survival signals [133]. The family comprises 18 α- and 8 β-
subunits, which can form at least 24 different non-covalently bound heterodimers [134]. 
Each of the monomers consists of a large extracellular, a transmembrane and a quite 
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short intracellular domain, of which only the β-subunit contains two tyrosine residues 
which are prone for phosphorylation [135]. Integrins were first discovered to solely act as 
adhesion molecules but for several years, it is getting clearer that they take part in 
various aspects of cell behaviour, like proliferation, survival and motility [136]. Integrin 
knock-out studies support the broad expression spectrum and the varying duties of the 
diverse integrin subtypes. Ablation of integrin genes can either lead to embryonic 
lethality (β1 knock-out) or give rise to normal mouse development (β5 knock-out) 
(reviewed in [137]).  
 
The list of possible extracellular binding proteins is long and comprises, among others, 
laminins, collagens, fibronectin, vitronectin and osteopontin. [138]. All ligands share the 
crucial receptor recognition sequence Arg-Gly-Asp (RGD) which directly interacts with 
both subunits of the integrin heterodimer [139]. Whereas the positively charged arginine 
interacts with negatively charged side chains on the α-subunit, aspartic acid couples to a 
region on the β integrin, called MIDAS (metal ion-dependent adhesion site) [140]. It is 
still not fully understood, which structural rearrangements occur after ligand binding. A 
recent model suggests that after binding to ECM proteins, the two very flexible subunits 
undergo a scissor-like movement followed by a switchblade-like opening of the two 
extracellular parts of the integrin, which ends up in a highly accessible cytoplasmatic β-
subunit [141]. It is now more obvious that integrin activation is a multi-step process and 
that several conformational states can be achieved, which results in diverse ligand 
affinity levels.  
 
After ligand binding, integrins often cluster in caveolin-enriched regions within the 
membrane which are called focal adhesions [142]. These regions often comprise other 
molecules involved in signalling, as RTK and intracellular kinases (see above). Within 
the last decade it emerged as a fact that integrin and growth factor signalling are tightly 
interconnected. First evidence, however, was given nearly 30 years ago, when Src was 
found to be localized within focal adhesions and scientists were able to immunostain 
these sites with phosphotyrosine-specific antibodies [143, 144]. Direct proof was gained 
when physical interaction of integrins with growth factors was verified and integrin 
agonists were proven to phosphorylate growth factor target proteins [145, 146]. 
Additionally, several growth factor stimuli as EGF or PDGF but also the hormone insulin 
were shown to optimally activate cells only when bound to ECM [147]. Furthermore, 
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both RTK and integrins can act as mechanosensors in response to shear stress, where 
they translate mechanical stimuli into intracellular chemical signals [148].  
 
In vascular biology, several integrins were shown to play essential roles in adhesion and 
signalling: α1β1, α2β1, α3β1, α5β1, α6β1, αVβ3, and αVβ5 respectively. On VSMC, α1β1, α2β1, 
α5β1, and αVβ3 are found to be expressed. [149]. In vascular tissues αVβ3 is of particular 
interest since both, αV  and β3 single knock-out mice display severe defects concerning 
intestinal vasculature and show inhibited platelet aggregation [150, 151]. Furthermore, 
several independent studies discovered major implications of αVβ3 in diverse signalling 
pathways. Co-immunoprecipitation studies revealed that αVβ3 interacted with PDGFR 
and influenced PDGF-triggered migration, αVβ3 ligands enhanced survival in an EGF-
dependent manner and furthermore prolonged EGFR phosphorylation. αVβ3 antagonists 
on the other hand induced apoptosis in proliferating endothelial cells, suggesting a 
survival-specific role for αVβ3 [152-154]. Additionally, various studies examined the role 
of αVβ3 in different diseases. Antagonists to αVβ3 inhibited the progression of breast 
cancer and neovascular diseases as rheumatoid arthritis and even diminished the 
infection rate of hanta-, and rotaviruses [155-157]. αVβ3 was furthermore shown to be 
involved in the migration of VSMC during restenosis (renarrowing of blood vessels after 
angioplasty) [158].  
 
As mentioned above, the cytoplasmatic domain of the β integrin contains two tyrosine 
residues which can be phosphorylated and serve as recognition sequences for SH2-
containing proteins like Shc. Since integrins do not contain a catalytic domain, other 
kinases have the ability to trans-phosphorylate β-subunits of integrins. However, 
phosphorylation is not mandatory since proteins expressing SH3 domains are able to 
bind to the cytoplasmatic tail of integrins in a phosphorylation-independent manner, 
which represents even the bigger pool of integrin interaction partners [159, 160]. 
Enzymatically inactive talin and vinculin are both linking integrins to the intracellular actin 
network [161]. Contrarily, kinases, phosphatases and adapter proteins actively 
contributing to several signalling events also bind directly to integrins, as integrin-linked 
kinase (ILK), Src, GRB2, paxillin or Shp-2 [160]. Of exceptional importance is focal 
adhesion kinase (FAK) which is linked to integrins either via paxillin or Src and 
influences both integrin and growth factor signalling.  
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2.5. Focal adhesion kinase, the main link from integrins to growth 
factors 
 
FAK was first discovered 1992 independently by two groups as a non-receptor kinase 
mainly found within focal adhesions [162, 163]. The family of FAK comprises only two 
members: FAK and proline-rich tyrosine kinase 2 (PYK2). FAK is widely expressed in 
nearly all tissues, whereas PYK2 is predominantly found in brain tissue and to a low 
extent in liver, spleen, kidney, lung and the hematopoietic system [164]. Moreover, 
truncated versions of FAK and PYK2, FAK-related non-kinase (FRNK) and PYK2-
related non-kinase (PRNK), are expressed in certain tissues and act as dominant-
negative regulators of FAK and PYK2 signalling [165]. Due to its wide expression 
pattern, FAK knock-out mice die early in embryogenesis but mesodermal cells obtained 
from these embryos at day 8 showed a reduced migration and spreading capacity, 
indicating the important role of FAK in cell motility. However, these cells exhibited 
normal focal contact formation, which means that FAK is not obligatory in these 
processes [166]. Interestingly, FAK knock-out embryos exhibit severe vascular defects, 
as they fail to develop blood vessels which highlights a crucial role for FAK in 
vasculogenesis [167].   
 
FAK is a 125 kDa protein that contains an N-terminal FERM (protein 4.1, ezrin, radixin 
and moesin homology) domain, which serves as docking site for growth factor receptors 
[168]. Moreover, it can interact with actin-binding proteins like ezrin and mediates 
recruitment of non-receptor tyrosine kinases to RTK or integrins [169]. The FERM 
domain can furthermore be sumoylated leading to enhanced FAK activity and nuclear 
translocation [170]. The centrally located catalytic domain is followed by a C-terminal 
focal adhesion targeting (FAT) domain, which serves as docking site for GRB2, paxillin 
and talin, all adapter proteins which target FAK to integrins within focal contacts [171]. 
Between the kinase domain and the FAT domain, two proline-rich regions can be found, 
which provide binding sites for SH3-containing proteins, such as GTPase regulator 
associated with FAK (GRAF) and p130Cas (p130 Crk-associated substrate), the latter 
important for promotion of migration (Fig. 3) [172].  
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Figure 3: Schematic representation of FAK with selected interaction partners 
FAK is able to autophosphorylate itself at Tyr397, which serves as docking site for Src and PI-3K. 
Src is able to further phosphorylate FAK at Tyr576/577, Tyr861 and Tyr925. The latter is an important 
binding region for structural or adapter proteins such as GRB2. Furthermore, paxillin binds and 
connects FAK to integrins. Proline-rich motifs (P1-P3) display anchoring sites for SH3-containing 
proteins such as p130Cas. The N-terminal FERM-domain couples FAK to RTK. For abbreviations, 
see section G. 
 
 
Of particular importance is binding of Src to phosphorylated Tyr397 near the proline-rich 
region (P1, Fig. 3), since Src is able to phosphorylate FAK at Tyr576/577, which together 
with the autophosphorylation site Tyr397 facilitates full FAK activity [173]. FAK-bound Src 
on the other hand undergoes conformational changes resulting in an even higher 
activation status of Src. Moreover, phosphorylated Tyr397 can be recognized by several 
other SH2-containing proteins, as PI-3K, PLC, Shp-2 and other members of the Src 
family [174]. Beside Tyr576/577, residues Tyr861 and Tyr925 can be phosphorylated by Src, 
the latter becoming a recognition site for the adapter GRB2, linking FAK signalling to the 
Ras pathway [175]. Tyr861 on the other hand, is very poorly characterized and it is still 
unknown which consequences emerge when FAK becomes phosphorylated at this 
specific residue. After growth factor stimulation or during mitosis, one serine residue 
within the FAT domain can get susceptible for phosphorylation, too [176]. However, the 
molecular effects of serine phosphorylation of FAK are still under investigation.  
 
The main substrates of FAK are paxillin and p130Cas, which can be phosphorylated by 
the active Src-FAK complex. Crk (CT10 sarcoma oncogene cellular homologue) can 
then bind to phosphorylated paxillin and p130Cas, which leads to enhanced migration 
potential upon activation of small GTPases. Inhibition of FAK activity can occur either via 
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dephosphorylation or via binding of inhibitor proteins to the catalytic domain of FAK, 
such as FAK-inhibitory protein 200 kDa (FIP200). Phosphatases reported to be able to 
bind to and dephosphorylate FAK are LMW-PTP or Shp-2 [177].  
 
The activity of FAK can be influenced by diverse input signals, from integrins to growth 
factors. Thereby, the multiple tyrosine residues of FAK act as a platform for many 
different interaction proteins and because of this, FAK plays an indispensable role in 
multiple signal transduction pathways. It has been clearly shown, that FAK is necessary 
for cells to survive and resist anoikis, a term describing apoptosis as a result of loss of 
adherence [178]. Moreover, FAK is indispensable in various aspects of cell motility. Due 
to its very upstream position in signalling, it is still unknown in which way certain signal 
inputs lead to specific and well-timed arrangements of FAK-protein complexes and to 
very distinct downstream effects. Future work will contribute new knowledge to current 
open questions of FAK activation.  
 
 
2.6. Molecular basics of VSMC migration 
 
The term migration describes the orchestrated and directed movement of cells towards 
a target area. Chemotaxis includes migration towards a gradient of a chemotactic 
stimulus, for example a growth factor [179]. At the molecular level, migration starts with 
the transduction of a chemoattractant stimulus from the cell surface to the cytoplasm, 
where coordinated cytoskeleton rearrangements lead to the polarization of the cell. At 
the leading edge, actin polymerization induces the formation of extensions, which show 
high adhesiveness to the substratum due to newly formed focal contacts [180]. 
Simultaneously at the rear end, focal contacts disperse and the myosin machinery is 
responsible for the trailing of the cell’s back side towards the stimulus. Moreover, it has 
to be ensured that all organelles move with the cytoskeleton towards the leading edge. 
By attaching the subcellular structures to motor proteins, they can move along the 
microtubules [181]. Of particular importance is the microtubule organizing centre 
(MTOC), where polymerization events of α and β tubulin take place. MTOC is located in 
front of the nucleus near the leading edge and is also involved in cell polarization events 
[182]. In general, actin filaments are considered to be responsible for the maintenance 
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of the cell shape and microtubules are stronger involved in trafficking duties, like 
organelle and protein shuttling.  
 
Two types of transmembrane proteins play the central role in cell movement: integrins, 
which loosen or tighten the connection to the ECM and growth factor receptors (RTK 
and GPCR). As already mentioned above, PDGF is the most important pro-migratory 
stimulus for VSMC [183]. Additionally, Ang II, TGF-β, thrombin, HB-EGF, EGF but also 
collagens, ATP, glucose or serotonin are reported to act as migration stimuli for VSMC 
(reviewed in [184]). On the other hand, different agents inhibit VSMC migration: hypoxia-
inducible factor-1 (HIF-1), interleukin-1β, interleukin-10, epinephrine, dopamine or cAMP 
(also reviewed in [184]). Moreover, physical factors can affect the migration potential of 
VSMC, like shear stress or blood flow [185, 186]. PDGF-BB is furthermore able to 
indirectly enhance and prolong migration by influencing the expression of EGF and 
fibroblast growth factor (FGF), which are both able to act in an autocrine fashion [187]. 
In vivo, migration is not triggered by a single stimulus which is often used in vitro but is 
rather a result of a diverse cocktail of chemoattractants and anti-migratory stimuli. At the 
molecular level, in vivo migration is orchestrated by several signalling cascades which 
probably cross-talk to each other [188]. One example is the proven migration-enhancing 
cross-talk between PDGFR and sphingosine-1 phosphate (S1P) receptor [189].  
 
At the intracellular site, actin polymerization at the plus end and disassembly at the 
minus end of filaments is a central step for cells to move forward. Actin assembly is 
orchestrated by formins with the help of small GTPases. This leads to the activation of 
Wiskott-Aldrich syndrome protein (WASP) and WASP family verprolin-homologous 
protein (WAVE), which in turn induces the actin-related protein 2/3 (ARP2/3) complex 
[190]. Other concentrated areas are focal contacts at the cell membrane, where both 
signalling proteins, such as Src and FAK, and structural proteins, as paxillin, vinculin or 
tensin, are located [191, 192]. The important development of new focal contacts at the 
leading edge of a migrating cell depends on the following steps: ligation and clustering 
of integrins, intracellular phosphorylation events of target proteins and the resulting 
assembly of filamentous actin (F-actin) structures [193]. Beside protein phosphorylation 
(for example FAK and paxillin), additional activity of calpains and MMP, which are able 
to cleave proteins within focal contacts, has been described to be an inevitable event in 
VSMC migration [194, 195]. Increase in intracellular Ca2+ furthermore induces migration, 
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as elevated Ca2+ activates myosin light chain kinase (MLCK), a direct activator of the 
motor protein myosin II [196].   
 
The small GTPases Rac1, RhoA and cdc42, which build up the subgroup of Rho family 
GTPases, share 80-90% homology with each other [197]. As the trimeric GPCR-coupled 
large G proteins, they belong to the superfamily of G proteins. In contrast to the trimeric 
molecules, they comprise only one subunit which is similar to the α-subunit of the large 
G proteins. Small GTPases get activated by exchanging GDP for GTP with the help of 
guanine nucleotide exchange factors (GEF). GTPase activating proteins (GAP) on the 
other hand accelerate hydrolysis of GTP to GDP and act as negative regulators of the 
small GTPases (Fig. 4). Furthermore, guanine dissociation inhibitors (GDI) minimize the 
spontaneous GDP-GTP exchange and hold GTPases in an inactive state [198]. Proteins 
of the Rho family do not only contribute to all stages of migration (Fig. 4), but are also 
involved in other cellular events such as transcription, survival or cell cycle progression 
[197, 199, 200]. Several stimuli have been demonstrated to activate Rho GTPases in 
VSMC, among others EGF and PDGF [201, 202]. Although induced very early in 
migration, studies report that FAK is situated upstream of Rho A and is able to activate it 
[203]. There are, however, reports which put FAK rather downstream of the Rho 
GTPases [204].  
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Figure 4: Signalling proteins involved in migration  
Upon growth factor binding, small GTPases Rac1, cdc42 and RhoA become activated and initiate 
distinct signalling pathways to form accurately defined actin substructures. Figure from Chelly et 
al. 2001, adopted. 
 
 
In VSMC, the number of direct downstream effector proteins of Rho GTPases is big. 
Rho A is directly activating Rho-associated coiled-coil-containing protein kinases 
(ROCK1/2) which phosphorylate and inactivate myosin light chain phosphatase (MLCP), 
leading to enhanced myosin contractility [205]. Furthermore, Rho A activates LIM kinase 
which enhances stress fibre formation (parallel microfilament bundles containing F-actin) 
[206]. The central downstream effector of both cdc42 and Rac1 is p21-activated kinase 
(PAK). PAK has been shown to exert many different effects on cytoskeleton proteins. 
On the one hand, it phosphorylates LIM kinase and MLCP, both promoting migration 
[207] and on the other hand it is able to phosphorylate cortactin and caldesmon, which 
enhances actin depolymerization and stress fibre disassembly [208, 209]. Thus, it is still 
unclear how PAK activation leads to coordinated cell movement. Rac1 is moreover 
involved in lamellipodia formation (branched protrusions at the front edge of a migrating 
cell) where it facilitates the formation of the ARP 2/3 complex, responsible for actin-
branching [210]. Cdc42 on the other hand was shown to be mainly responsible for 
filopodia development. These spike-like actin bundles are tightly engaged with structural 
proteins as fimbrin and emerge from the very front of the moving cell. These “tentacles” 
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are the first regions where new adhesion sites are formed and focal contacts emerge 
[211].  
 
Cell migration is a tightly orchestrated rearrangement of the whole cytoskeleton of a cell. 
Although many molecular key players are well known it is still astonishing, how certain 
stimuli lead to either cell growth or migration. Intracellularly, it is also very interesting that 
master regulators such as GTPases are able to process one signal input to specific 
downstream effects. Future work will hopefully provide more insight, how signal 
specificity is guaranteed within a cell.  
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3. Resveratrol 
 
 
The polyphenolic compound resveratrol (RV, Fig. 5) is a phytoalexin, a molecule which 
certain plants produce in response to injury, stress, UV light or infection, and which is 
predominantly found in berries, nuts and grapes [212]. It was first discovered to be the 
active compound in a Japanese plant (Polygonum cuspidatum), used against diseases 
such as dermatitis and gonorrhoea [213]. In 1976 it was first detected to be produced in 
grapevines (Vinis vitifera) and was later on also quantified in red wine [214, 215]. RV is 
discussed to play a major role in explaining the French paradox, which is the fact that in 
certain regions of France the risks to develop cardiovascular diseases are very low, 
although the traditional diet is rich in saturated fatty acids. Additionally, in France the 
consumption of red wine is highest in Europe and therefore this is discussed to 
counteract the unhealthy eating habits [216].  
 
 
 
Figure 5: Chemical structure of RV 
 
 
The amounts of RV detected in red wine range from 1 to 26 µM [217]. The 
concentrations can vary, since many parameters influence RV production in grapes: sun 
exposure, cultivar or previous fungal infections. White wine contains only little amounts 
of RV because it is, unlike red wine, fermented without the fruits and RV is not found in 
the juice but in high concentrations in the skins [215]. 
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 In the last decade, a lot of effort was made to scientifically proof the health-beneficial 
effects of RV. Indeed, it has become clear that RV can affect a plethora of different 
molecular targets and can act also systemically. A major molecular effect of RV is its 
antioxidative property. It was shown, that RV can counteract oxidation of LDL, an 
important step in the initiation of atherosclerosis [218]. Furthermore, it also inhibited the 
cellular uptake of oxidized LDL [219]. Intracellularly, RV was shown to influence the 
activity of certain endogenous antioxidants, as catalase, glutathione reductase or 
glutathione-S-transferase [220]. Neuro- and cardioprotective heme oxygenase-1 was 
shown to be induced by RV, too [221]. In ApoE-deficient mice, an animal model for 
inducible hypercholesterolemic atherosclerosis, RV enhanced ischemia-induced 
neovascularization [222]. RV also inhibited the aggregation of platelets, which can occur 
in late stages of atherosclerosis [223]. In humans, red wine intake went along with 
enhanced antioxidant activity measured in serum [224]. When using cultured VSMC, RV 
was shown to inhibit proliferation and ROS production [225, 226]. It blocked moreover 
both Ang II- and EGF-induced Akt phosphorylation [227].  
 
Among the diverse effects of RV, its anti-inflammatory and immunomodulatory capacity 
should be mentioned. It was shown, that RV affects the activity of cyclooxygenases 
(COX) both in vitro and in vivo [228, 229]. In macrophages, LPS-induced iNOS 
activation was reduced by RV and the expression of adhesion molecules on 
polymorphonuclear (PMN) cells was diminished by addition of RV [230, 231]. At the 
transcriptional level, RV was documented to affect the activity of NF-κB by either 
inhibiting I-κB phosphorylation or by abolishing nuclear translocation of p65 [232, 233]. 
Since NF-κB is a transcription factor involved in diverse cellular processes ranging from 
apoptosis to inflammation [234], molecules as RV are of particular interest for clinicians 
and researchers. Furthermore, RV inhibits the activity of another important transcription 
factor, activator protein-1 (AP-1) and was shown to be able to act both as agonist or 
antagonist for the estrogen receptor (ER) mainly by its structural similarity to estrogen 
[233, 235, 236]. It is also proven that RV can act as an anti-invasive compound, since it 
diminishes migration of certain cancer cells in part by affecting the phosphorylation 
status of FAK [237, 238]. Direct interactions of RV with distinct cell components have 
been observed, ranging from surface receptors as integrins to cytoplasmatic proteins or 
even nuclear molecules including DNA [239-241]. 
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Remarkable effects have been documented when administering RV systemically. Baur 
and colleagues demonstrated that RV supplementation (22.4 mg/kg/d) in mice 
counteracted the physiological parameters of a high-calorie diet, as elevated body 
weight, decreased motor function or low insulin sensitivity [242]. Similarly, another study 
revealed that RV (4 g/kg food/d) enhanced mitochondrial function, muscle strength and 
endurance of both standard- and high fat diet-fed mice [243]. Experiments using a short-
lived fish showed that supplementation of RV (24-600 µg/g food/d) to the standard food 
enhanced lifespan and diminished age-related immobility and loss of cognitive 
competence [244]. In this context, RV is often referred to as caloric restriction (CR) 
mimetic, because an attenuation of food intake by 30% is a well-known possibility to 
prolong the life-span of model organisms [245]. In both models for life-span extension 
activation of sirtuin 1 (SIRT1), a histone deacetylase, has been shown to be crucial [243, 
246].  
 
Due to its apoptosis-inducing and anti-proliferative effects RV has been discussed not 
only to exert beneficial effects, since the specificity of RV to target cancer cells is not 
given [247]. Additionally, RV was documented to induce senescence (permanent cell 
cycle arrest, in which cells do not respond to any stimulus) in human endothelial cells 
[248]. Moreover, in vivo bioavailability of RV is very low as a result of diminished 
intestinal uptake and short half-life due to rapid metabolism (8-14 minutes) [249]. Until 
now, it is not fully understood if metabolites of RV can act as active substances, since 
such molecules are considered to exert reduced cell permeability [250].   
 
 
 
Previous studies in our lab documented that 50 µM RV inhibited both, Ang II- and EGF-
mediated Akt phosphorylation, whereas p38 phosphorylation remained unaffected by 
the polyphenol. While both, EGF-triggered and Ang II-induced activation and 
phosphorylation of the EGFR was not influenced by RV, the interaction between EGFR-
associated Gab1 and p85 was inhibited by the polyphenol [227, 251]. However, the 
direct molecular target of RV in this specific context was not found so far. 
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4. Rationale and aims of the study 
 
 
Today, it is well known that RV exerts many health-beneficial qualities, especially in the 
area of cardiovascular diseases. However, beside the versatile phenotypic 
cardioprotective properties, the cellular and molecular actions of RV are poorly 
characterized. We therefore wanted to gain more insight into the anti-migratory and anti-
hypertrophic actions of RV in growth factor-induced VSMC.  
Integrins and the direct downstream kinase FAK are not only important key 
players in adhesion and migration, they play also important roles in growth factor 
signalling and survival. We wanted to unravel, if integrin αVβ3 or FAK are involved in the 
potent inhibitory actions of RV on Akt phosphorylation via possible direct receptor 
binding, changes in the phosphorylation levels or alterations in the interaction capacity 
with target molecules. Moreover we tried to elucidate, if estrogen signalling is 
contributing to EGF-mediated Akt phosphorylation and if RV could therefore exert its 
inhibiting abilities through a possible antagonism to the estrogen receptor. As the 
antioxidative properties of RV are well-studied, we furthermore tried to unravel if VSMC 
are able to produce extracellular ROS after growth factor stimulation and if RV can affect 
this, which might contribute to RVs inhibitory effects on VSMC. Migration of VSMC 
towards the site of inflammation is one initial event in the early phases of atherosclerosis. 
We therefore wanted to know, if RV can negatively affect migration of VSMC and if so, 
what the molecular key players are. 
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C  Materials and experimental procedures 
 
 
 
1. Chemicals 
 
Unless otherwise stated, all chemicals were obtained from Sigma Aldrich (including RV; 
St. Louis, MO, USA) Carl Roth (Karlsruhe, Germany) or Fluka (Buchs, Switzerland). 
EGF was purchased from Millipore (Temecula, CA, USA), Beriglobin was obtained from 
Behring (Vienna, Austria), PDGF was purchased from Bachem (Weil am Rhein, 
Germany) and CompleteTM was bought from Roche (Penzberg, Germany). 
 
RV was diluted in DMSO yielding a 50 mM stock solution, which was stored at -80°C for 
further usage. EGF was resolved in PBS to a concentration of 100 µg/ml and preserved 
at -20°C. Ang II and PDGF were dissolved in PBS containing 0.25% BSA. Ang II was 
stored in 2 mM aliquots at -80°C, PDGF stocks (10 ng/µl) were kept at -20°C, 
respectively. Estrogen (β-estradiol) was dissolved in 96% ethanol and kept at -80°C in 
10 mM aliquots. 
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2. Buffers 
 
 
PBS pH 7.4 NaCl 7.2 g 
autoclaved Na2HPO4 1.48 g 
 KH2PO4 0.43 g 
 ddH2O ad 1000 ml 
PBS+  NaCl 8.0 g 
sterile-filtered (0.22 µm) KCl 0.2 g 
 Na2HPO4 1.15 g 
 KH2PO4 0.2 g 
 MgCl2 x 6 H2O 0.1 g 
 CaCl2 x 2 H2O 0.1 g 
 ddH2O ad 1000 ml 
FACS buffer pH 7.4 NaCl 8.12 g 
sterile-filtered (0.22 µm) KH2PO4 0.26 g 
 Na2HPO4 2.35 g 
 KCl 0.28 g 
 LiCl 0.43 g 
 NaN3 0.20 g 
 Na2EDTA 0.36 g 
 ddH2O ad 1000 ml 
Krebs-Ringer phosphate glucose  NaCl 145 mM 
buffer (KRPG) Na2HPO4 5.70 mM 
pH 7.4 KCl 4.86 mM 
stored at 4°C CaCl2 x H2O 0.54 mM 
 MgSO4 x 7 H2O 1.22 mM 
 Glucose 5.50 mM 
        Amplex Red™ reagent KRPG 3.64 ml 
        protected from light HRP 1 U/ml 75 µl 
 10 mM Amplex Red™ 37.5 µl 
10x Electrophoresis buffer Tris-base 30 g 
stored at 4°C Glycine 144 g 
 SDS 10 g 
 ddH2O ad 1000 ml 
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Table 1: Buffers used for various experiments 
 
 
 
 
 
5x Blotting buffer Tris-base 15.2 g 
stored at 4°C Glycine 72.9 g 
 ddH2O ad 1000 ml 
        1x Blotting buffer 5x blotting buffer 200 ml 
        stored at 4°C Methanol 200 ml 
 ddH2O ad 1000 ml 
TBS-T pH 8.0 Tris-base 3.0 g 
stored at 4°C NaCl 11.1 g 
 Tween-20 1 ml 
 ddH2O ad 1000 ml 
Cytoskeleton buffer (CB) NaCl 150 mM 
pH 6.1 EGTA 5 mM 
 MgCl2 5 mM 
 Glucose 5 mM 
 MES (2-(N-morpholino) -  10 mM 
 ethanesulfonic acid  
        CB-1 CB 4.75 ml 
 Triton-X (10%) 250 µl 
 Glutaraldehyde 5 ml 
        CB-2 CB 9.90 ml 
 Glutaraldehyde 100 µl 
Digestion buffer Collagenase (246 U/mg) 0.1 g 
 HEPES 0.24 g 
 Ascorbic acid 0.005 g 
 Gentamycin sulfate 0.005 g 
 BSA 0.1 g 
 Ham´s F12 medium ad 100 ml 
 (PAN biotech, Germany)  
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3. Cell culture 
 
Rat VSMC were isolated from thoracic aortas of male Sprague-Dawley rats by 
enzymatic digestion [252]. Aortic tubes were collected from three to four sacrificed 
animals and transferred to PBS+-containing dishes. Connective tissue was removed by 
scratching and aortas were subsequently transferred to dishes containing prewarmed 
digestion buffer. After an incubation phase of approximately 15 minutes, the tubes were 
cut longitudinally and the inner surfaces of the aortas were disposed from endothelial 
tissue by scraping. Aortas were then chopped into small pieces and seeded in 75 cm2 
flasks containing prewarmed cell culture medium. After a few days of incubation, VSMC 
emigrated from the aortic tubes to the bottom of the flask where they started to 
proliferate. When confluence was reached, VSMC were frozen in aliquots of 1 x 106 
cells/ml and then stored in liquid nitrogen. For all experiments, VSMC isolated by the 
same method and kindly provided by Kathy K. Griendling (Emory University, Atlanta, 
USA) were used.  
 
VSMC between passage 7 and 15 were used for all experiments. Cells were cultured in 
Dulbecco´s Modified Eagles Medium (DMEM) at 37°C and 5% CO2. Cells were 
passaged when 90% confluence was reached by detaching with Trypsin-EDTA. For 
experimental approaches, cells were seeded either in 6-well or 24-well plates or in 6 cm 
or 10 cm dishes for two to three days, respectively. Before stimulation VSMC were 
serum-starved by incubation with DMEM containing 0.1% CS, antibiotics and L-
glutamine for 24 to 48 hours.  
 
Mouse fibroblasts expressing an exon 3-deleted version of Shp-2 (a gift from Benjamin 
Neel, Yale University, Connecticut, USA) were cultivated in cell culture medium 
containing 10% CS, 2 mM glutamine, 100 units/ml penicillin and 100 μg/ml streptomycin 
at 37°C and 5% CO2. Cells were seeded in gelatine-coated 10 cm dishes and serum-
starved in DMEM containing 0.2% CS for 24 hours before stimulation.  
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Cell culture medium DMEM (Lonza, Switzerland) 500 ml  
 Calf serum (CS) (Lonza) 55 ml  
 Penicillin (Lonza) 10.000 U/ml  
 Streptomycin (Lonza) 10.000 U/ml  
 L-glutamine (Lonza) 200 mM  
Starving medium DMEM 500 ml 
 Calf serum 500 µl 
 Penicillin (Lonza) 10.000 U/ml  
 Streptomycin (Lonza) 10.000 U/ml 
 L-glutamine (Lonza) 200 mM 
Trypsin/EDTA in PBS Trypsin 0.05% 
sterile-filtered (0.22 µm) EDTA 0.02% 
Freeze medium DMEM  8.0 ml 
 CS 2.0 ml 
 DMSO 1.1 ml 
Table 2: Cell culture material utilized for experiments  
 
 
4. Whole cell lysates 
 
After stimulation, VSMC were lysed as described elsewhere [227]. Briefly, cells were 
washed twice with ice-cold PBS and incubated with an appropriate volume of cold lysis 
buffer containing protease and phosphatase inhibitors for 15 minutes at 4°C. VSMC 
were scraped off, transferred to pre-cooled 1.5 ml tubes and subsequently spun in a 
table-top centrifuge for 10 minutes at 4°C with full speed to pellet insoluble material. 
Supernatants were aspirated, transferred to new tubes, frozen in liquid nitrogen and 
stored at -80°C until further usage. For protein quantification, Bradford method was used 
like previously described and recommended in the manufacturer’s guidelines [253]. For 
Western Blot, an adequate amount of protein lysate was mixed with 3 x SDS-PAGE dye 
and heated for 5 minutes at 95°C before loading samples onto gels.  
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 5. Western Blot 
 
Western Blot method was used to determine changes in protein expression levels and 
was applied as previously described [254]. 20 to 30 µg of protein was loaded onto 7.5-
15% SDS-PAGE gels and electrophoresis was carried out at 55-125 V for 60 to 90 
minutes (Biorad, CA, USA). Thereafter, gels were blotted at 120 mA per blot for 90 
minutes (Biorad, CA, USA) and membranes were blocked for 1 hour at room 
temperature with TBS-T containing 5% non-fat milk. Prior to incubation with 
appropriately diluted primary antibody at 4°C over night, the membranes were washed 
three times with TBS-T. Secondary antibody was incubated for 1 hour at room 
temperature and membranes were analyzed using a densitometer (LAS-3000™, Fujifilm, 
Japan).  
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Target Conjugated Source Dilution or Concentration Application Provider 
α-actin FITC mouse, mc 1:250 IF Sigma Aldrich 
Akt  rabbit, pc 1:1000 WB Cell Signaling 
phospho-Akt-Ser473  rabbit, pc 1:1000 WB Cell Signaling 
αV integrin  rabbit, pc 3 ng/µl FACS Santa Cruz 
β3 integrin PE hamster, mc 1.5 ng/µl FACS Invitrogen 
β3 integrin  rabbit, pc 1:1000 WB Cell Signaling 
β3 integrin  mouse, mc 20 µg/ml blocking BD Pharmingen 
cdc42  rabbit, mc 1:1000 WB Cell Signaling 
DNA-Polymerase  goat, pc 1:200 WB Santa Cruz 
ERα  mouse, mc 1:500 WB Thermo 
FAK  rabbit, pc 1:1000 WB Cell Signaling 
phospho-FAK-Tyr397  mouse, mc 1:1000 WB BD Transduction 
phospho-FAK-Tyr576/577  rabbit, pc 1:1000 WB Cell Signaling 
phospho-FAK-Tyr861  goat, pc 1:500 WB Santa Cruz 
phospho-FAK-Tyr925  rabbit, pc 1:1000 WB Cell Signaling 
goat IgG HRP bovine, pc 1:2500 WB Santa Cruz 
mouse IgG HRP goat, pc 1:1000 WB Upstate 
rabbit IgG HRP goat, pc 1:2500 WB Cell Signaling 
rabbit IgG FITC goat, pc 3 ng/µl FACS Invitrogen 
Rac1  mouse, mc 1:1000 WB Cell Biolabs 
Shp-2  rabbit, pc 1:1000 WB Santa Cruz 
tubulin  mouse, mc 1:500 WB Santa Cruz 
Table 3: Antibodies used in various experiments: HRP, horseradish peroxidase; IF, 
immunofluorescence; IgG, immunoglobulin G; FACS, fluorescence-activated cell sorting; FITC, 
fluorescein isothiocyanate; mc, monoclonal; pc, polyclonal; PE, phycoerythrin; WB, Western Blot  
 
 
6. Immunoprecipitation 
 
In order to confirm protein-protein interactions or the phosphorylation status of a specific 
protein, immunoprecipitation experiments were conducted as explained elsewhere [227]. 
Cells were lysed as specified above and 250-500 µg of protein was adjusted to 1 µg/µl 
with lysis buffer containing protease, and phosphatase inhibitors. 600 ng-2 µg of 
antibody was added and samples were incubated over night at 4°C in a rotator (LTF, 
Wasserburg, Germany). Next, 25 µl of prewashed protein A/G agarose beads (Santa 
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Cruz, CA, USA; 1:1 in PBS) per sample were added and incubated for additional 2 
hours. After three times of washing, immunoprecipitated proteins were mixed with 15 µl 
of 3 x SDS-PAGE dye and heated for 5 minutes at 95°C before applying to SDS-PAGE.  
 
 
7. FACS 
 
For the determination of the surface expression pattern of proteins on VSMC, FACS 
(fluorescence-activated sell sorting) was utilized. The protocol was mainly used as 
stated elsewhere [255]. 5 x 105 VSMC were harvested, washed and transferred into 
FACS tubes and subsequently resuspended in 50 µl PBS containing 0.5% BSA and 
0.1% azide. 5 µl Beriglobin (1:8 working solution in PBS/BSA/azide) was added and the 
cells were incubated on ice for 5 minutes. Then, cells were incubated with 10 µl of the 
proper diluted, directly fluorescence-conjugated or unconjugated primary antibody for 
20-30 minutes at 4°C in the dark. In case of using an unconjugated first-step antibody, 
samples were washed twice in FACS buffer and incubated for additional 30 minutes with 
a fluorescence-labelled secondary antibody at 4°C in the dark. The suspension was 
washed once more with FACS buffer and finally once with PBS. Cells were immediately 
analyzed with the FACSCalibur™ cytometer (BD Biosciences, Mountain View, CA, USA) 
 
 
8. Amplex Red Assay 
 
The non-fluorescent compound Amplex RedTM (10-acetyl-3,7-dihydroxyphenoxazine; 
Invitrogen, CA, USA) is a substrate of horseradish peroxidase (HRP) and is able to be 
converted into resorufin in the presence of H2O2 in a 1:1 stoichiometry [256]. Since 
Amplex RedTM is not entering living cells, it is highly suitable to measure H2O2 which is 
released by cells [257]. VSMC were grown in 24-well plates and serum-starved for 24 
hours. Cells were washed once with prewarmed PBS before the KRPG buffer containing 
the Amplex RedTM reagent was applied to the cells. Plates were incubated for 15 
minutes at 37°C before VSMC were stimulated with different compounds for 5-45 
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minutes. 80 µl of the supernatant was transferred into 96-well plates to measure 
produced resorufin in triplicate with a fluorometer (Genios Pro, Tecan, Switzerland).  
 
 
9. Cytoplasmatic versus nuclear extracts 
 
To obtain nuclear extracts, VSMC were grown in 10 cm dishes. After starvation, cells 
were stimulated and washed twice with ice-cold PBS. Adherent cells were gently 
detached in 1 ml of PBS by scraping, transferred into precooled 1.5 ml tubes and 
centrifuged for 5 minutes with 3.500 rpm at 4°C. After aspirating the PBS, pelleted cells 
were resuspended in 300 µl of ice-cold buffer A and incubated for 15 minutes on ice. 
Before vigorous vortexing, 15 µl of 10% NP-40 was added and lysates were spun for 30 
seconds with full speed at 4°C in a table-top centrifuge. Supernatants containing the 
cytoplasmatic fractions were transferred into new tubes for further usage. The pellets 
containing the nuclear fractions were aspirated in 50 µl ice-cold buffer B. Extracts were 
incubated for 15 minutes of reciprocal shaking and insoluble material was separated 
from the nuclear protein fraction by centrifugation with full speed for 4 minutes at 4°C. 
The protein concentration of both fractions was quantified by Bradford method before 
loading on SDS-PAGE gels. 
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Lysis buffer (stock solution) HEPES 50 mM 
for whole cell extracts NaCl 50 mM 
pH 7.5  NaF 50 mM 
stored at 4°C Na4P2O7 x 10 H2O 10 mM 
 EDTA 5 mM 
 Na3VO4 1 mM 
   
? prior to use stock solution 850 µl 
 Triton X-100 (10%) 100 µl 
 PMSF (100 µM) 10 µl 
 CompleteTM 40 µl 
Nuclear extracts (Buffer A) HEPES (100 µM) 1000 µl 
cytoplasmatic fraction KCl (100 µM) 1000 µl 
stored at 4°C EGTA (10 µM) 100 µl 
 EDTA (10 µM) 100 µl 
 ddH2O ad 10 ml 
   
? prior to use Buffer A 1988 µl 
 DTT (1 M) 2 µl 
 PMSF (100 µM) 10 µl 
Nuclear extracts (Buffer B) HEPES (100 µM) 1000 µl 
nuclear fraction NaCl (5 M) 400 µl 
stored at 4°C EGTA (500 µM) 10 µl 
 EDTA (500 µM) 10 µl 
 Glycerol 1250 µl 
 ddH2O ad 5 ml 
   
? prior to use Buffer B 98 µl 
 DTT (100 µM) 1 µl 
 PMSF (100 µM) 1 µl 
Table 4: Different cell lysis buffers 
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10. Wound healing assay 
 
For the quantification of VSMC migration, wound healing assays were performed. VSMC 
were grown in 6-well plates to 95% confluence and serum-starved for 24 hours. For 
each well, two scratches were made using a sterile 100 µl-1000 µl tip and detached cells 
were washed away subsequently. Thereafter, starving of VSMC was continued for 
additional 24 hours. Before induction of migration, scratches were photographed with 
200-fold magnification (Light Microscope Olympus CKX31; Olympus Live View Digital 
SLR Camera E-330, Hamburg, Germany). After 21 hours of migration, pictures of the 
same scratch area were taken and paired images were analyzed to quantify the 
narrowing of scratches (cell profiler software, Broad Institute Imaging Platform). 
 
 
11. Fluorescence microscopy 
 
2 x 105 VSMCs were seeded on coverslips in 12-well plates over night, washed with 
PBS and fixed with ice-cold Aceton/Methanol (1:1) for 15 minutes at 4°C. After washing 
with PBS, coverslips were placed onto droplets of diluted α-smooth muscle actin-FITC 
antibody (1:250 in PBS containing 1% BSA) and incubated for 1 hour at 4°C in the dark. 
Coverslips were washed twice with PBS, mounted onto glass slides and left over night 
to dry in the dark at 4°C. Samples were then analyzed with a fluorescence microscope 
(BX51 microscope, Olympus, Hamburg, Germany). 
 
To visualize the actin cytoskeleton of VSMC, 5 x 104 cells were seeded on coverslips as 
mentioned above. Cells were serum-starved for 24 to 48 hours and then treated with 
different stimuli. After washing with PBS, cells were incubated for 1 minute with 
prewarmed CB-1 buffer. After aspirating the supernatant, VSMC were subsequently 
covered with a layer of prewarmed CB-2 buffer for 15 minutes at room temperature. 
Samples were washed three times with PBS and incubated with a 1:200 dilution of 
phalloidin-FITC for 30 minutes at room temperature in the dark. Plates were rinsed three 
times with PBS before mounting on glass slides. Samples were dried over night at room 
temperature and then acquired with a fluorescence microscope (BX51 microscope, 
Olympus, Hamburg, Germany).  
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12. GTPase assay 
 
Agarose beads exclusively binding to GTP-bound GTPases can be used to easily pull 
down only the active fraction of a pool of proteins. For our purpose, we used PAK1 PBD 
Agarose beads (Cell Biolabs, CA, USA) which specifically bind and precipitate active 
Rac1 and cdc42 [207]. VSMC were seeded in 10 cm dishes and grown to 90% 
confluence. After 48 hours of serum starvation cells were stimulated and lysed by 
scraping (lysis buffer from Cell Biolabs, CA, USA; 1:5 in ddH2O). Before IP, crude cell 
lysates were precleared and insoluble material was pelleted (4 minutes, full speed, 4°C). 
Afterwards, 20 µl of the lysate was taken away for loading control and the remaining 
volume was mixed with 20 µl of bead slurry. Immunoprecipitations were incubated for 45 
minutes at 4°C in a rotator and then washed three times with lysis buffer. Beads were 
mixed with 15 µl of 3 x SDS-PAGE Dye and cooked for 5 minutes at 95°C before loading 
on 15% SDS-PAGE gels.  
 
 
13. Computer software 
 
Name Version Provider 
AIDA (Advanced Image Data Analyzer) 4.06 Raytest Inc 
CellProfiler 1.0.5122 Broad Institute Imaging Platform 
Cell Quest Pro 5.2 BD Biosciences 
GraphPad PRISM™ 4.03 GraphPad Software Inc 
Image Reader LAS 3000™ 2.0 Fujifilm 
Magellan 5.03 Tecan 
ViCell™ XR 2.03 Beckman Coulter 
Table 5: Computer software used for evaluation of raw data  
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14. Statistical Analysis 
 
All data are expressed as means ± SEM. Statistical analyses were performed using two-
tailed, paired t-tests unless otherwise noted. P < 0.05 was considered significant. All 
tests were evaluated using GraphPad PRISMTM software. Statistical comparisons were 
always done to vehicle-treated cells unless otherwise mentioned.  
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D  Results 
 
 
 
1. Isolation and identification of vascular smooth muscle cells 
 
 
Rat aortic vascular smooth muscle cells were isolated as described in the chapter 
materials and experimental procedures. Five days after isolation, VSMC were seeded 
onto cover slips and stained with an antibody specific for rat α-smooth muscle actin. Fig. 
6 shows that all detected cells were stained positive and the isolated batch of VSMC 
was not contaminated with other cell types of aorta-surrounding tissue.  
 
 
 
 
 
 
 
 
 
 
Figure 6: α-smooth muscle actin 
staining of VSMC 
Fluorescence microscope picture 
showing rat vascular smooth muscle 
cells in passage one after isolation 
from the aorta. Cells were stained with 
a monoclonal and FITC-labelled rat-
specific α-smooth muscle actin 
antibody (200-fold magnification). 
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2. Influence of RV on EGF- and Ang II-induced Akt 
phosphorylation 
 
 
Phosphorylation of Akt is one central molecular event in cell survival, hypertrophy and 
proliferation. RV was shown to potently prevent both EGF- and Ang II-triggered 
phosphorylation of Akt [227]. After 24 hours of serum starvation, VSMC were stimulated 
with either 100 ng/ml EGF for 5 minutes or 100 nM Ang II for 10 minutes, respectively. 
RV was added 30 minutes before growth factor stimulation. Cells were subsequently 
washed with ice cold PBS and lysed. Fig. 7 shows that Akt was strongly phosphorylated 
when treated with EGF. Sustained Akt phosphorylation was also documented when 
stimulated with Ang II. In both cases of stimulation, RV was potently preventing the 
phosphorylation of Akt (75% inhibition in EGF-treated cells and complete abrogation of 
Akt phosphorylation in Ang II stimulated VSMC), whereas total Akt amounts remained 
unaffected. These results go along with previous published data of our lab [227]. 
 
 
 
Figure 7: RV interferes with EGF- and Ang II-induced Akt phosphorylation 
VSMC were preincubated with 50 µM RV for 30 minutes before inducing Akt phosphorylation with 
100 ng/ml EGF for 5 minutes or 100 nM Ang II for 10 minutes, respectively. 20 µg of protein was 
loaded onto SDS-PAGE gels and Western Blot membranes were blotted against pAkt and total 
Akt. One representative blot is shown. 
 
 
Based on these findings, we wanted to elucidate the molecular mechanisms underlying 
the potent inhibitory actions of RV on Akt phosphorylation and tried to find putative 
molecular target molecules which are affected by RV. 
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3. Possible targets for RV to inhibit the phosphorylation of Akt 
 
 
3.1. The role of the estrogen receptor α  in the process of EGF-
mediated Akt phosphorylation 
 
Since RV has been shown to act as a selective estrogen receptor mediator (SERM) in 
certain cell systems in vitro [235, 236], we wanted to know if estrogen receptor (ER) 
signalling is playing a role in our experimental setting of rapid Akt activation. We first 
determined the protein expression of ERα in VSMC by Western Blot and detected, 
beside the ERα full length version of 67 kDa also an unknown ~55 kDa protein, which 
was highly enriched in the nuclear fraction, but was not further investigated (Fig. 9A). As 
a next step, we asked whether estrogen stimulation could lead to Akt phosphorylation in 
a similar manner as EGF did. We set up a time-kinetic experiment, stimulating serum-
starved VSMC for 2 to 30 minutes with 100 nM estrogen (Fig. 8A). Indeed, estrogen was 
able to significantly increase Akt phosphorylation with a maximal 2.5-fold induction after 
2 minutes of stimulation and a 2.1-fold enhancement after 5 minutes of estrogen 
stimulation. However, compared to EGF-mediated Akt phosphorylation (20- to 30-fold 
induction above basal levels), the capacity of estrogen to induce Akt phosphorylation 
was much lower. By preincubating VSMC for one hour with 10 µM of fulvestrant, a 
selective ER antagonist, estrogen-triggered Akt phosphorylation was abrogated 
indicating that Akt phosphorylation through estrogen stimulation was mediated via a 
direct involvement of the ER (Fig. 8B).  
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Figure 8: Estrogen stimulation leads to enhanced pAkt levels via direct ERα contribution 
(A) 100 nM estrogen was used to treat VSMC for the indicated time periods. Western Blot 
analyses of (phospho) Akt were performed to quantify the relative phosphorylation status of Akt. 
Bar graph shows the summary of five independent experiments, where densitometric analyses 
are normalized to vehicle control (E2, estrogen; **, p < 0.01; ns, not significant; mean ± SEM; 
one-way ANOVA). (B) VSMC were preincubated with 10 µM fulvestrant for 1 hour and 
subsequently stimulated with estrogen for 5 minutes. Western Blot analyses of four experiments 
are summarized in the graph with one representative blot above (Fvstr, fulvestrant; E2, estrogen; 
*, p < 0.05; mean ± SEM). 
 
 
Due to its chemical structure, estrogen passes the cell membrane and binds to ER in the 
cytoplasm. ER then dimerizes and translocates to the nucleus to bind to its specific ER 
response elements on DNA [258]. Beside this “classical” genomic activation pathway, 
rapid signalling events including membrane-bound ER also take place in some cell 
systems [259]. To exclude the genomic pathway of ER signalling, we extracted 
cytoplasmatic and nuclear proteins after stimulating VSMC with different combinations of 
50 µM RV (30 minutes preincubation) and 100 ng/ml EGF or 100 nM estrogen (5 
minutes each). In none of the stimulation conditions, ER was shuttled to the nucleus 
demonstrating that nuclear translocation and ER-mediated initiation of transcription did 
not occur in our chosen experimental setting of rapid signalling (Fig. 9B).  
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Figure 9: Estrogen-induced Akt phosphorylation is triggered via a non-genomic pathway 
(A) Unstimulated VSMC were used to obtain whole cell extracts (WCE), cytoplasmatic extracts 
(CE) and nuclear extracts (NE) Western Blot membranes were incubated with antibodies against 
ERα and tubulin. (B) VSMC were incubated with the indicated stimuli (preincubation with RV for 
30 minutes followed by 5 minutes stimulation with either estrogen or EGF) and cytosolic versus 
nuclear extract were made. Proteins were separated by SDS-PAGE and membranes were 
blotted against ERα, tubulin (cytoplasmatic fraction purity control) and DNA-polymerase (nuclear 
fraction purity control). One representative blot is depicted. 
 
 
It has been demonstrated that ERα can be located at membranes in proximity to EGFR 
and furthermore is able to contribute to Akt signalling [97]. To test if RV could inhibit 
estrogen-induced Akt phosphorylation as well, VSMC were treated with 100 nM 
estrogen after 30 minutes of RV incubation (50 µM). RV pretreatment strongly inhibited 
estrogen-mediated Akt phosphorylation. Moreover, additional preincubation with 
fulvestrant 1 hour before RV treatment did not influence the potent phosphorylation-
inhibiting properties of RV on Akt (Fig. 10A).  
 
Furthermore, fulvestrant was utilized in EGF-treated VSMC as well, where we treated 
smooth muscle cells for 1 hour with fulvestrant before adding RV for additional 30 
minutes. Finally, EGF was added to the cells at concentrations of 100 ng/ml for 5 
minutes. Fig. 10B shows, that fulvestrant neither changed EGF-mediated Akt 
phosphorylation nor RV´s dephosphorylating effects on Akt. Taken together, these 
results indicate that RV can act as a potent antagonist of ERα but a contribution of ERα 
to EGF-induced Akt activation could not be documented. 
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Figure 10: ER signalling does not contribute to RV effects on EGF-induced pAkt 
(A) VSMC were incubated with 50 µM RV (30 minutes) with or without pretreatment of fulvestrant 
for 30 minutes. Cells were then stimulated with 100 nM estrogen for 5 minutes, lysates were 
separated by SDS-Page and blotted. Densitometric values of phospho-Akt were correlated to 
total Akt protein amounts (*, p < 0.05; mean ± SEM, n = 4). (B) Cells were pretreated with 10 µM 
fulvestrant for 30 minutes before administration of 50 µM RV for additional 30 minutes. Cells 
were subsequently stimulated with 100 ng/ml EGF for 5 minutes. Western blot analyses were 
quantified densitometrically (ns, not significant; mean ± SEM, n = 4). 
 
 
 
3.2. Integrins as possible target of RV 
 
One very important role of integrins is to anchor single cells with each other and to the 
meshwork of extracellular matrix (ECM) and therefore stabilizing the cells within the 
tissue [133]. Furthermore integrins play an important role in growth factor-mediated 
signalling events [146]. Previous studies revealed that RV was able to bind to integrin 
αVβ3 in cancer cells, thereby triggering ERK 1/2 and p53 phosphorylation [241]. We 
therefore wanted to examine a putative role of the cell adhesion molecule integrin αVβ3 
in VSMC either as possible binding site for RV or as candidate molecule which 
contributes to the inhibiting effects of RV on Akt phosphorylation. Firstly, the surface 
expression pattern of integrin αVβ3 on VSMC was determined. Unstimulated cells were 
incubated with different fluorescence-labelled antibodies specific for either subunit of the 
integrin αVβ3 and then analyzed by FACS. As shown in Fig. 11, αV as well as β3 integrin 
monomers were weakly expressed on the surface of untreated rat VSMC. Furthermore, 
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pretreatment with RV or EGF for 2 to 48 hours did not change the surface expression 
levels of αV and β3 (not shown).  
 
 
 
Figure 11: Surface expression pattern of αVβ3 integrins on VSMC  
(A) FACS histogram showing integrin αV surface expression. Cells were first incubated for 1 hour 
with unconjugated rabbit anti-αV antibody, washed and a secondary, FITC-labelled anti-rabbit 
antibody was added for another hour. As negative control, rabbit-IgG isotype control treated cells 
were used. Logarithmic fluorescence intensity is plotted against cell number. Black line indicates 
control-stained cells, red line αV-stained cells. (B) VSMC were stained with directly conjugated 
β3-PE antibody. As negative control, unstained cells were utilized. Histogram plot depicts 
logarithmic fluorescence intensity against cell number. Black line shows unstained cells, green 
line β3-PE stained VSMC. 
 
 
Next we wanted to know if, and to what extent integrin αVβ3 accounts for the inhibiting 
actions of RV on Akt phosphorylation. VSMC were preincubated with 50 or 500 µM of a 
small peptide Arg-Gly-Asp (RGD), which is the recognition motif of many integrin-binding 
proteins [138]. In a second experimental approach, cells were preincubated with 20 
µg/ml of a monoclonal blocking antibody against β3 integrin. After 2 hours of either RGD 
or β3 antibody incubation, cells were treated with RV for additional 30 minutes before 
stimulation with 100 ng/ml EGF for 5 minutes. Western Blot analyses showed, that 
pretreatment with either of the integrin blocking agents, 500 µM RGD and 20 µg/ml anti-
β3 antibody, could counteract the inhibiting actions of RV on Akt phosphorylation to a low, 
but significant extend (Fig. 12A and B). Pretreatment with either 50 µM of RGD or 
control antibody did not change the inhibiting effects of RV on pAkt.  
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Figure 12: Effects of blocking molecules on RV-mediated dephosphorylation of Akt 
VSMC were treated with 100 ng/ml EGF for 5 minutes. 50 μM RV was added 30 minutes before 
EGF stimulation. (A) RGD blocking peptides at indicated concentrations were preincubated 2 
hours before RV addition. Bar graph shows densitometric analysis of phospho-Akt band 
intensities correlated to total Akt amounts. One representative blot is shown above (**, p < 0.01; 
mean ± SEM; n = 5). (B) 20 µg/ml of a monoclonal anti-β3 blocking antibody was preincubated 2 
hours before RV treatment. As negative control, an unspecific IgG isotype-ident antibody was 
used at same concentrations. Bar graph shows phospho-Akt band intensities related to total Akt 
amounts. One representative blot is shown (ctrl, control antibody; β3, monoclonal anti-β3 integrin 
antibody; *, p < 0.05; mean ± SEM; n = 5).  
 
 
Moreover, we could observe by Western Blot analysis that  β3 expression levels were 
downregulated by 20% only in the case of 2 hours preincubation with anti-β3 antibody 
and subsequent stimulation with both RV and EGF (Fig. 13). In experiments using RGD 
blocking peptides, no significant changes in β3 expression could be observed (data not 
shown).  
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β3 integrins contain two important phosphorylation-sensitive tyrosine residues at the 
cytoplasmatic C-terminus [135]. We tried to unravel, whether RV could affect the 
phosphorylation status of β3 integrin and therefore influences integrin signalling. 
Unfortunately, we were not able to immunoprecipitate β3 integrin to check possible 
phosphorylation changes within the molecule and therefore cannot exclude that RV 
potentially influences integrin phosphorylation. Furthermore, we speculated that 
integrins expressed on adherent and highly confluent VSMC would mostly be bound to 
target structures on neighbouring cells or connected to ECM. If RV acted via binding to 
integrins, multiple free and unbound integrins would positively influence the impact of 
RV´s inhibiting properties. However, the adherence and confluence status of VSMC had 
no influence on diverse stimuli since detached cells reacted equally to EGF and RV 
administration as attached VSMC (Fig. 14).  
 
 
 
 
Figure 13: Downregulation of β3-integrin 
expression after incubation with anti-β3 
blocking antibody 
VSMC were pretreated with 20 µg/ml anti-β3 
antibody for 2 hours. 50 μM RV was added 
30 minutes before EGF stimulation (100 
ng/ml, 5 minutes). After stimulation, cell 
lysates were subjected to Western Blot. Bar 
graph is expressed as x-fold control of β3 
integrin expression correlated to tubulin 
levels. One representative blot is shown (ctrl, 
control antibody; β3, monoclonal anti-β3 
antibody; *, p < 0.05; ns, not significant; 
mean ± SEM; n = 5). 
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Figure 14: Detachment has no influence on the inhibiting actions of RV 
100% confluent VSMC were trypsinized, spun and reseeded into new dishes containing starving 
medium (“detached”) or left adherent (“attached”). RV was pretreated for 30 minutes and cells 
were stimulated with 100 ng/ml EGF for 5 minutes. Western Blot shows one representative blot of 
pAkt and totat Akt amounts. 
 
 
In summary, we conclude that integrin αVβ3 is clearly not the main target molecule of RV 
concerning its inhibitory properties on Akt phosphorylation, although a minor 
participation of this specific integrin might take place. 
 
 
 
3.3. Influence of RV on FAK phosphorylation 
 
Since FAK is one crucial and central molecule in mediating both RTK and integrin 
signals downstream of the referred receptors [168], we wanted to know if the activity and 
phosphorylation status of FAK was affected by RV, which possibly accounted for the 
impaired Akt phosphorylation. First experiments with EGF-stimulated cells revealed, that 
100 ng/ml EGF led to a significant FAK dephosphorylation by approximately 20% (p < 
0.05) which could be completely counteracted by preincubation with RV (Fig. 15A). 
Since EGF-triggered dephosphorylation of FAK could be due to inhibition of a kinase or 
activation of a phosphatase, we preincubated VSMC with 50 µM of the phosphatase 
inhibitor sodium ortho-vanadate (Na3VO4). Preincubation with Na3VO4 for 30 minutes 
completely restored the phosphorylation status of FAK, indicating that EGF was able to 
activate one or more phosphatases which in turn led to dephosphorylation of FAK (Fig. 
15B) 
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Figure 15: EGF-initiated FAK dephosphorylation is reversed by RV and mediated by 
phosphatases 
(A) After preincubation with 50 µM RV or vehicle for 30 minutes, VSMC were stimulated with 100 
ng/ml EGF for additional 5 minutes. Cell lysates were obtained and 250 µg of protein was 
immunoprecipitated with anti-FAK antibody overnight. Western blot membranes were first probed 
with anti-phospho tyrosine antibody. For loading control, membranes were stripped and 
reincubated with anti-FAK antibody (*, p < 0.05; **, p < 0.01; mean ± SEM, n = 4). (B) 50 µM of 
Na3VO4 was added to VSMC for 30 minutes followed by 5 minutes stimulation with 100 ng/ml 
EGF. After lysis of cells, immunoprecipitations with anti-FAK antibody were carried out overnight. 
Precipitates were subjected to Western Blot and membranes were probed with anti-phospho 
tyrosine antibody and anti-FAK antibody, respectively. One representative blot is shown. 
 
 
Since the involvement of Shp-2 in growth factor-mediated FAK signalling is well 
described [177], we checked whether Shp-2 was involved in the EGF-mediated 
dephosphorylation process of FAK. We conducted co-immunoprecipitation experiments 
stimulating VSMC for 5 minutes with EGF with or without pretreatment with RV. In 
comparison to unstimulated or RV-pretreated cells, a significant higher amount of Shp-2 
could be co-immunoprecipitated with FAK in EGF-stimulated cell lysates (20% 
enhancement), indicating a direct link between FAK dephosphorylation and elevated 
FAK-Shp-2 interaction (Fig. 16).  
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Another proof for this hypothesis was gained when aforementioned experiments were 
repeated in cells expressing a truncated version of Shp-2 (Shp-2Δ46-110). These cells lack 
the N-terminally located exon 3 of Shp-2 and therefore the protein lost the ability to 
interact properly with possible target molecules [131]. Moreover, Shp-2Δ46-110 mouse 
fibroblasts express very little amounts of truncated Shp-2 compared to the expression 
pattern of wild-type Shp-2 in VSMC (Fig. 17A). In these cells, EGF and RV stimulation 
did not cause dephosphorylation of FAK but rather enhanced FAK´s phosphorylation 
status by 20-50 % (Fig. 17B). Moreover, no interaction between FAK and Shp-2Δ46-110 
could be observed (data not shown). In sum, these experiments underpin a direct 
influence of Shp-2 in the EGF-induced dephosphorylation process of FAK and a 
possible inhibiting role of RV regarding a FAK-Shp-2 interaction. 
Fig. 16: Enhanced Shp-2-FAK interaction is 
counteracted by RV  
Prior to stimulation with 100 ng/ml EGF for 5 minutes, 
VSMC were incubated with vehicle or 50 µM RV for 30 
minutes. Lysates were immunoprecipitated with anti-FAK 
antibody and Western Blot membranes were blotted 
against Shp-2 and FAK, respectively. One representative 
blot is shown. Bar graph shows summary of four 
independent experiments (*, p < 0.05; **, p < 0.01; mean 
± SEM). 
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Figure 17: Shp-2Δ46-110 fibroblasts do not show FAK dephosphorylation upon EGF 
treatment 
(A) Comparison of Shp-2 expression between VSMC and Shp-2Δ46-110 mouse fibroblasts. 
Unstimulated cells were lysed and 30 µg of protein was applied to SDS-PAGE. Membranes were 
incubated with anti-Shp-2 and anti-FAK antibody, respectively. (B) Shp-2Δ46-110 mouse fibroblasts 
were pretreated with 50 µM RV or vehicle for 30 minutes and then stimulated with 100 ng/ml EGF 
(5 minutes). 250 µg of cell lysate was used for immunoprecipitation of FAK. Phosphotyrosine 
bands were normalized to total FAK amounts. One representative blot is shown, bar graph 
represents four independent experiments (*, p < 0.05; ns, not significant; mean ± SEM). 
 
 
The 125 kDa protein FAK is strongly regulated via phosphorylation of several distinct 
tyrosine residues within the molecule [173]. To unravel the involvement of the different 
phosphorylation sites of FAK in EGF signalling, we used four phospho-specific 
antibodies covering the most important and well described phosphorylation sites of FAK. 
Whereas phosphorylation of Tyr397, which serves as hallmark for FAK activity, was 
significantly downregulated by 20% by both EGF and additional RV treatment, the 
residues Tyr576/577 were hyperphosphorylated by EGF and additional RV stimulation (Fig. 
18). Furthermore, no significant changes could be observed when investigating tyrosine 
residues Tyr861 and Tyr925. The size of FAK on the one hand and its several 
phosphorylation sites on the other hand, makes it a perfect molecule to interact with a 
big number of different proteins. After verifying clear differences between the distinct 
phosphorylation sites of FAK, we wanted to take a deeper look into possible protein-
protein interaction changes as a result of phosphorylation alterations.  
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Figure 18: Single phosphorylation sites of FAK are differently regulated by EGF and RV 
Schematic representation of the FAK molecule showing all phosphorylation-prone tyrosine 
residues. Prior to EGF stimulation (100 ng/ml for 5 minutes) smooth muscle cells were pretreated 
with 50 µM RV or vehicle for 30 minutes. For immunoprecipitation, 250-500 µg of protein lysate 
was incubated over night with anti-FAK antibody. Different phospho-specific antibodies were 
used for Western blot and band intensities were normalized to total FAK levels. Bar graphs 
represent three to four independent experiments (*, p < 0.05; **, p < 0.01; ns, not significant; 
mean ± SEM). 
 
 
Unfortunately, all proteins which we investigated were not co-immunoprecipitated with 
FAK. These proteins include Src, PI3K, Akt and Gab-1 (data not shown). Our results 
reveal that different phosphorylation sites of FAK are very unequally affected by EGF 
and RV. However, changes in interaction patterns between FAK and target proteins 
could not be observed. We therefore cannot exclude a putative role of RV in these 
processes of direct or indirect protein-FAK interactions.  
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3.4. Extracellular H2O2 production is vigorously decreased by RV 
 
RV is well known to act as an antioxidative molecule and both, intracellular and 
extracellular produced ROS are indispensable second messengers in cell signalling [218, 
220, 260]. By utilizing Amplex RedTM, which exclusively detects extracellularly produced 
H2O2, we observed that unstimulated VSMC steadily generated H2O2 which led to high 
basal levels of extracellular hydroxide peroxide. Both Ang II and EGF were able to 
trigger enhanced production of extracellular H2O2 in a time-dependent manner (Fig. 19). 
Whereas EGF stimulation led to increasing accumulation of H2O2 peaking after 15 
minutes of stimulation (20% above basal levels, Fig. 19A), Ang II treatment revealed that 
H2O2 production was highest after 10 minutes (15% above basal levels) descending 
again at later time points (Fig. 19B).  
 
 
 
Figure 19: RV extenuates both basal and Ang II- or EGF-induced extracellular H2O2 levels 
(A) VSMC were stimulated in Amplex Red buffer with EGF (100 ng/ml) for 5 to 15 minutes after 
preincuabtion with RV or vehicle control for 30 minutes. Produced H2O2 was quantified using a 
fluorometer. Absolute values were correlated to catalase-treated cells used as negative control. 
Graph shows relative extracellular H2O2 production expressed as x-fold vehicle-treated cells (–□–, 
vehicle-treated cells; –■–, RV-treated cells; ***, p < 0.001; mean ± SEM; n = 4). (B) Cells were 
treated and analyzed as indicated in (A) except the usage of Ang II (100 nM) as stimulant. (–□–, 
vehicle-treated cells; –■–, RV-treated cells; ***, p < 0.001; mean ± SEM; n = 4). For all statistical 
analyses, vehicle-treated cells were correlated to RV-treated cells for each time point separately 
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However, pretreatment with RV for 30 minutes strongy reduced both, basal H2O2 levels 
and growth factor-induced H2O2 production. RV decreased H2O2 levels down to 40% of 
basal levels, no matter if EGF or Ang II were applied or not.  
 
In summary, we found that RV acts as a very potent neutralizing molecule for 
extracellular H2O2 and is able to compensate basal and growth-factor induced levels of 
H2O2 in VSMC, therefore possibly influencing signalling mediated by extracellularly 
produced H2O2. 
 
 
 
In the context of EGF-mediated rapid Akt phosphorylation, we investigated possible 
target molecules of RV, which could explain the very potent inhibitory actions of RV. We 
were able to demonstrate, that ERα does not contribute to EGF-mediated 
phosphorylation of Akt, although RV showed anti-estrogenic capacity. Furthermore, we 
could show that integrin αVβ3 has only minor influence on the inhibitory actions of RV on 
pAkt. FAK may contribute to the effects of RV, but most likely does not completely 
explain the inhibitory actions of RV. Moreover, RV acts as H2O2 neutralizer, which 
possibly influences also intracellular signalling events.  
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4. Anti-migratory effects of RV on growth factor-induced VSMC 
 
 
 4.1. EGF induces migration of VSMC 
 
As RV is a potent anti-invasive compound already described in different cancer cell lines 
and VSMC migration plays a pivotal role especially in the early stages of atherosclerosis 
[22, 237], we asked whether RV is able to inhibit migration of VSMC. We conducted 
wound healing assays, where a scratch was applied to a confluent monolayer of serum-
starved cells. After 24 hours of serum deprivation, smooth muscle cells were stimulated 
with different concentrations of EGF for 21 hours to initiate migration. The rate of cells 
which migrated within 21 hours was microscopically evaluated and quantified (see 
materials and methods section for details). While 1 ng/ml EGF only slightly induced 
migration of VSMC, stimulation with 10-100 ng/ml EGF resulted in a dose-dependent 
increase of migration (Fig. 20A). 20 ng/ml EGF led to a 50% increase, which could not 
be enhanced by applying higher concentrations of EGF. We therefore decided to use 20 
ng/ml of EGF for all subsequent experiments to initiate migration. Furthermore we made 
sure that observed effects were indeed due to VSMC migration and not mediated via 
EGF-induced proliferation or cell hypertrophy. By using mitomycin C, a potent and well-
known inhibitor of proliferation, migration rates initiated by EGF did not change 
significantly (Fig. 20B). 
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Figure 20: EGF induces migration of VSMC in a dose-dependent manner 
(A) Different concentrations of EGF have been used to induce migration in wound healing assays. 
Photos were made before and after 21 hours of stimulation with indicated concentrations of EGF 
and were then evaluated. Bar graph shows summary of three independent experiments (**, p < 
0.01; ns, not significant; mean ± SEM; one-way ANOVA). (B) Before induction of migration (20 
ng/ml EGF for 21 hours) VSMC were incubated with 100 nM mitomycin C or vehicle for 30 
minutes. Wound healing assay photos were evaluated as described in materials and 
experimental procedures. Graph depicts summary of three experiments (*, p < 0.05; ns, not 
significant; mean ± SEM). 
 
 
 
4.2. RV abrogates EGF-induced but not PDGF-induced migration 
 
Next we wanted to know if RV was able to block EGF- or PDGF-induced migration. 
PDGF is even a stronger migration stimulus as EGF and is normally used in 
concentrations of 2-10 ng/ml ([261] and data not shown). Wound healing assays were 
performed as described before using 20 ng/ml of EGF and 2 ng/ml PDGF. Prior to 
growth factor stimulation, 50 µM of RV was added for 30 minutes. Fig. 21A shows 
representative pictures of wound healing assays before and after an incubation period of 
21 hours where different stimuli were applied. While RV was able to completely block 
EGF-induced migration, it could not reduce PDGF-triggered migration to a significant 
extent.  
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Figure 21: RV blocks EGF-induced but not PDGF-mediated migration 
(A) Representative photos from scratch assays before and after a stimulation time of 21 hours. 
RV was preincubated for 30 minutes and EGF (20 ng/ml) or PDGF (2 ng/ml) was added for 21 
hours  (200-fold magnification). (B) and (C) Bar graphs represent changes in the migration 
capacity of VSMC after 21 hours of stimulation with indicated compounds. Arbitrary units were 
normalized to vehicle-treated cells and are expressed as x-fold control (*, p < 0.05; **, p < 0.01; 
***, p < 0.001; ns, not significant; mean ± SEM; n = 3-5). 
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Fig 21B and C summarize evaluations of three to five independent wound healing 
assays. Whereas RV reduced EGF-mediated migration by 67%, a slight but non-
significant migration decrease in PDGF-triggered VSMC could be observed. RV´s 
diverse effects were not due to the chosen growth factor concentrations, since RV was 
still able to block EGF-, but not PDGF-induced migration, when even higher 
concentrations of the growth factors were used (not shown).  
 
To unravel possible differences of action of RV when using either EGF or PDGF as 
stimuli, we employed cytoskeleton stainings of VSMC using phalloidin-FITC which binds 
to actin bundles within the cell. Fig. 22 shows representative photographs of phalloidin-
stained cells after 2 hours of EGF or PDGF stimulation (20 ng/ml and 2 ng/ml, 
respectively) with or without RV pretreatment (50 µM for 30 minutes), where a clear 
morphological difference could be observed.   
 
 
 
Figure 22: RV reduces lamellipodia formation of EGF- but not of PDGF-treated VSMC 
RV-preincubated cells (50 µM for 30 minutes) were stimulated with EGF (20 ng/ml) or PDGF (2 
ng/ml) for 2 hours, respectively. After washing and fixation, cells were stained with FITC-
conjugated phalloidin for 30 minutes to visualize the actin structures of the cytoskeleton. Dried 
samples were monitored using a fluorescence microscope. Arrows indicate developed 
lamellipodia (400-fold magnification). 
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Both, EGF and PDGF led to evident cytoskeleton rearrangements after 2 hours 
indicating the activation of migration pathways. Sustained formations of lamellipodia 
(indicated with arrows) and stress fibres could be monitored. Pretreatment with RV 
abrogated lamellipodia formation in EGF- but not in PDGF-stimulated VSMC leading to 
a more round-shaped morphology in the case of EGF-treated cells. On the contrary, 
addition of RV had no clear effect on stress fibre formation in either EGF- or PDGF-
stimulated VSMC. 
 
 
 
4.3. RV does not influence hyperphosphorylation of FAK 
 
FAK plays a pivotal role in both, rapid signalling cascades distributing incoming integrin 
or growth factor signals, and long term actions referred to chemotaxis, like cytoskeleton 
rearrangement or actin stabilization [166]. We therefore wanted to know, if FAK 
phosphorylation is changed over a prolonged time frame of EGF stimulation. For this 
purpose, we established time course experiments monitoring the overall phosphorylation 
status of FAK by immunoprecipitation. Fig. 23A clearly shows that a dynamic process of 
phosphorylation and dephosphorylation events takes place, where a first 20% increase 
of FAK phosphorylation could be observed after 2 hours of EGF stimulation. However, 
FAK reached an even higher phosphorylation level after 8 hours of stimulation (60% 
induction) which was followed by a subsequent drop to basal levels until the end of the 
time course experiments after 17 hours. 
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Figure 23: Long-term stimulation with EGF induces hyperphosphorylation of FAK after 8 
hours which is not affected by RV 
(A) Smooth muscle cells were stimulated with 100 ng/ml EGF for the indicated time periods. 250 
µg of protein was used for immunoprecipitation with anti-FAK antibody. Immunoblots were first 
probed with anti-phospho tyrosine antibody, then incubated with anti-FAK antibody. Graph shows 
summary of three to four individual experiments (*, p < 0.05; **, p < 0.01; ns, not significant; 
mean ± SEM; one-way ANOVA). (B) VSMC were pretreated with vehicle or 50 µM RV and then 
challenged with 100 ng/ml EGF for 8 hours. Immunoprecipitations (250 µg protein with anti-FAK 
antibody over night) were loaded onto PAA-gels and separated by electrophoresis. 
Phosphotyrosine band intensities were calculated against total FAK amounts (*, p < 0.05; ns, not 
significant; mean ± SEM; n = 3-4). 
 
 
Thereafter we asked the question, whether RV can influence hyperphosphorylation of 
FAK after 8 hours of EGF administration. VSMC were preincubated with 50 µM of RV 
and then stimulated with 100 ng/ml EGF for 8 hours. Pretreatment with RV, however, 
had no significant effect on the elevated phosphorylation status of FAK (Fig. 23B). Long 
term experiments using PDGF as stimulus gained equal results. PDGF slightly induced 
FAK phosphorylation which was not affected by preincubation with RV (data not shown). 
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4.4. Rac1 is the molecular reason for the anti-migratory activity of RV 
  
The molecular requirement for lamellipodia formation is mainly activation of the small 
GTPase Rac1, which we next investigated. By conducting pull-down assays where only 
GTP-bound Rac1 was immunoprecipitated, we could determine the molecular effects of 
RV on EGF- and PDGF-induced lamellipodia outgrowth. Fig. 24A depicts, that 20 ng/ml 
of EGF caused a 2.4-fold Rac1 activation after 5 minutes which was completely inhibited 
by preincubation of 50 µM RV. PDGF at 2 ng/ml induced a comparable Rac1 activation 
(2.5-fold), which was almost unaffected by RV (Fig. 24B). 
 
 
 
Figure 24: EGF- but not PDGF-activated Rac1 is strongly inhibited by RV 
For immunoprecipitating the active form of Rac1, VSMC were pretreated with RV for 30 minutes 
and then stimulated with 20 ng/ml EGF (A) or 2 ng/ml PDGF (B) for 5 minutes. Cells were 
subsequently lysed and an aliquot of each whole cell lysate was taken away for determination of 
total Rac1 amounts. The remaining lysate was incubated with PAK Agarose beads for 45 minutes. 
Immunoprecipitated active Rac1 was correlated to the whole Rac1 amounts. Bar graphs show 
summaries of three to four independent experiments with representative blots above (*, p < 0.05; 
**, p < 0.01; ns, not significant; mean ± SEM).  
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On the other hand cdc42 activity, which is responsible for filopodia development was not 
affected by either EGF or PDGF stimulation (Fig. 25). Moreover, RV had no effect on 
cdc42 activity, either.  
 
 
 
Figure 25: cdc42 activity is not affected by EGF, PDGF and RV 
Active cdc42 was immunoprecipitated for 45 minutes with PAK-agarose beads after stimulation 
with 20 ng/ml EGF (A) or 2 ng/ml PDGF (B) for 2 minutes. RV was added 30 minutes before 
growth factor stimulation. Before IP, whole cell lysate aliquots were drawn off. Representative 
Western Blots are shown. 
 
 
RhoA, molecular prerequisite for stress fibre formation, could not be precipitated and 
therefore we cannot definitely exclude that RhoA activity is influenced by RV. However, 
phalloidin stainings revealed no obvious changes of stress fibre formation (Fig. 22). With 
these experiments we could clearly show, that RV selectively affects lamellipodia 
formation in EGF-triggered VSMC, and therefore inhibits exclusively migration of EGF-
stimulated, but not PDGF-treated cells, which we moreover could document by Rac1 
pull-down experiments. 
 
 
 
Taken together, we could show that EGF induces migration in VSMC which is 
completely blocked by RV in a stimulus-dependent manner, since PDGF-mediated 
migration and lamellipodia formation is not affected by pretreatment with the polyphenol. 
At the molecular level, hyperphosphorylation of FAK is not affected by RV. Enhanced 
activity of Rac1 on the other hand, is strongly inhibited in EGF- but not in PDGF-
stimulated VSMC, which at least in part explains the growth factor-dependent anti-
migratory modes of action of RV.  
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E  Discussion 
 
 
The polyphenol RV has been described to be one main active compound which 
accounts for the health-beneficial effects of red wine and may be responsible, at least in 
part, to explain the French paradox [216]. It has already been shown, that RV exerts 
advantageous properties to diminish certain parameters of cardiovascular risk factors, 
as lowering LDL oxidation [218]. Since CVD are today’s most abundant illnesses in the 
world, much effort is made to find potent compounds to fight these diseases [5]. VSMC 
play a central role in many aspects of atherosclerosis, from the initiation to more 
progressive states of the disease [22]. The migration of VSMC into and subsequent 
proliferation within the intima of the atherosclerotic lesion mainly accounts for the 
narrowing of the atherosclerotic blood vessel [22]. Therefore, prevention of VSMC 
migration, proliferation and hypertrophy may improve the chances to delay or even 
circumvent the progression of atherosclerosis. It has been already shown, that RV 
influences Ang II- or EGF-induced Akt activation in VSMC and acts as antioxidative 
molecule to diminish ROS production [226, 227]. Until now it is not clear how RV exerts 
its manifold beneficial properties and which molecules are directly or indirectly affected 
by the molecular actions of RV.  
 
In search of the molecular target that accounts for RV-mediated inhibition of Akt 
phosphorylation upon EGF, we investigated a series of possible candidate proteins in 
this respect. 
 
 
RV can act as SERM, which means that it is able to bind to ER in an antagonistic or 
agonistic way, depending on the cellular system and concentration [235, 236]. Beside 
the “classical” genomic actions of ER, it has been demonstrated that the nuclear 
receptor can contribute also to rapid signalling cascades, where it is located near the 
membrane and can influence among others Akt signalling [97]. We wanted to determine 
if ERα contributes to EGF signalling and if RV was able to act as a SERM. We could 
clearly show that ERα was able to contribute to Akt phosphorylation in a rapid and non-
genomic way (Fig. 8A and 9B). In EGF-stimulated cells, however, participation of ERα 
was not taking place, since the selective ER antagonist fulvestrant neither changed 
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EGF-induced Akt phosphorylation nor the inhibiting effects of RV on pAkt. It seems that 
RV is able to bind to ERα at the ligand binding domain in an antagonistic fashion, since 
pretreatment of VSMC with RV followed by subsequent addition of estrogen strongly 
inhibited phosphorylation of Akt (Fig. 10A). Since these effects were even stronger than 
the influence of fulvestrant, we assume that RV is able to potently bind to ERα in an 
antagonistic way. Due to the structural similarity of estrogen and RV, it is likely that RV 
fits into the ligand binding domain of VSMC ERα , which has already been mentioned by 
others [262]. These results do not directly proof that RV acts as antagonist for ERα and 
results from co-incubation experiments with fulvestrant and RV implicate the possibility 
that RV either binds to another area within ERα which causes a synergistically inhibition 
of the receptor. However, it can be speculated that RV binds to the ligand binding 
domain of ERα with a higher affinity than fulvestrant, which may cause the latter to 
dissociate from its receptor. 
 
Furthermore possible effects on ERβ, which is also expressed in VSMC but only poorly 
described [263], were not determined. The molecular basics of rapid signalling of 
membrane-bound ER are not well studied and it is still not clear, whether a certain 
isoform of ER is responsible for the rapid signalling effects or if all ER subtypes are able 
to do so [264]. Moreover, several truncated versions of ERα have been discovered to be 
expressed in various tissues. One N-terminally deleted 46 kDa variant has raised the 
attention of several groups, because of its broad expression pattern and full functionality 
[265]. Moreover, it has been shown that the 46 kDa version of ERα was contributing to 
rapid signalling events in vascular endothelial cells and was located and membrane-
anchored in caveolae, which represent hotspots of signalling [265]. Although we used an 
antibody targeting the C-terminus of ERα, which means that also N-terminally deleted, 
short versions of ERα should be recognized by this antibody, we could not discover a 46 
kDa version in VSMC. However, a protein with approximately 55 kDa size was detected 
(Fig. 9A), which we solely found to be expressed in the nucleus of VSMC. Whether this 
protein is really a short ERα version or only an artefact of the antibody remains elusive. 
 
Taken together, we could show that rapid and non-genomic ER-mediated signalling 
towards Akt is occurring in our experimental setting of estrogen-stimulated VSMC. 
Although RV potently inhibited estrogen-mediated Akt phosphorylation, no contribution 
of ERα in EGF-mediated signalling could be monitored. 
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Integrins, the big family of transmembrane adhesion molecules, are pivotal sensors to 
control cell attachment to the surrounding ECM [133]. Integrins contribute to intracellular 
signalling mainly by binding adapter proteins and/or by phosphorylation of the β-subunit 
and therefore transmitting survival signals into the cell [138]. Since integrin signalling is 
able to contribute to different aspects of RTK signal transduction [146], we asked the 
question if the inhibiting properties of RV on Akt phosphorylation are mainly or at least in 
part transmitted via integrins. Recently, it has been demonstrated that RV can directly 
bind to a particular integrin, αVβ3 [241]. By using two cancer cell lines (MCF-7 and MDA-
MB) and purified integrin monomers, the group showed that especially the β3-subunit 
had the ability to bind RV. Furthermore, the interaction of RV with the integrin had also 
impact on the signalling, since blocking molecules inhibited the RV-dependent 
hyperphosphorylation of ERK 1/2 and p53. This report was the first one to show that 
integrins contain a receptor site for RV, which is moreover involved in signalling. 
Furthermore, it has already been shown that the αVβ3 integrins are expressed on rat 
VSMC [266], which was also confirmed by our group (Fig. 11).  
 
By preincubating VSMC with blocking molecules, as the small peptide RGD or β3-
blocking antibodies, we wanted to determine if the inhibiting effects of RV on EGF-
induced Akt phosphorylation could be influenced. However, preincubation of VSMC with 
both blocking molecules had only minor effects on the potential of RV to inhibit Akt 
phosphorylation (Fig. 12). In the case of using RGD peptides, it is still reasonable to 
assume that RV binds to a region within the integrin, other than the classical ligand 
binding site occupied by the RGD peptide. Although Lin and colleagues argue that RV 
binds at least to a region near the ligand binding domain [241], direct proof for this 
hypothesis remains elusive. By using the, in comparison to the RGD peptide, much 
bigger blocking antibody against β3 integrins we tried to occupy a large region within the 
integrin monomer. However, experiments using anti-β3 integrin antibodies yielded 
comparable results. This means that RV is mainly not acting via integrin αVβ3 to exert its 
inhibitory actions on Akt phosphorylation. It is still possible, however, that also the 
antibody binds to its target structure and leaves unoccupied regions for RV-binding, 
which we cannot exclude with these experiments. The concentrations of both blocking 
molecules were in accordance with other in vitro studies [241, 267]. Since the antibody 
is widely used as a rat-specific blocking molecule to prevent integrin-igand interaction, 
we can exclude that the antibody was not targeting the integrin on the surface of VSMC. 
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Since integrins are able to transduce signals via phosphorylation of the β-subunit and it 
was already shown that EGF affects integrin phosphorylation [268], we wanted to 
examine the phosphorylation status of β3 integrins when using EGF and RV as stimuli. 
On the one hand it was not possible to detect changes in the phosphorylation status of 
β3 integrin utilizing whole cell lysates. On the other hand we were not lucky to 
immunoprecipitate the β-subunit from the crude cell lysate, although different lysis 
buffers and antibodies were used. Since IP of β3 did not work at all, we cannot rule out 
possible changes in the phosphorylation status of β3 and furthermore of integrin-protein 
interactions when stimulating VSMC with EGF and RV. It is feasible that RV possibly 
acts intracellularly to selectively influence interactions between the β3 integrin and one or 
more interacting protein(s). In our experimental setting it would be interesting to examine 
especially the phosphatase Shp-2 or the kinases FAK and Src, since they were shown 
to directly interact with integrins and moreover play significant roles in growth factor 
signalling [66, 160, 269]. Interestingly, we observed that the β3 expression was 
significantly reduced when VSMC were incubated with a combination of blocking 
antibody, RV and EGF. It can be speculated, that the entry of RV into the cell may occur 
via receptor internalization, which is a well known phenomenon [270]. Unfortunately, this 
effect was not seen when RGD peptide or RV plus EGF alone were applied, which 
means that this result may be an artefact and β3 downregulation is due to the action of 
the blocking antibody per se.  
 
Another hint that integrins might not be the main target or entry site for RV was given, 
when we detached VSMC from their substratum and left them in suspension. We 
thought that if RV was able to bind integrins, detached VSMC which were not bound to 
ECM and therefore displaying solely unligated integrins on their surfaces would even 
amplify the inhibiting effects of RV on Akt signaling. Since suspended VSMC reacted 
exactly in the same way as adherent cells, this was another evidence that integrins 
might not be the primary target molecules of RV. Nevertheless, VSMC express at least 
four different integrin heterodimers (see introduction) and we therefore cannot definitely 
exclude that perhaps other integrin subtypes are more susceptible to RV-binding and 
may contribute to a bigger extent to the inhibiting effects of RV on Akt phosphorylation. 
Moreover, it was pretty difficult to find appropriate tools to detect species-specific 
integrin subunits, as this research field is quite new and very diverse.  
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In summary we could show, that integrin αVβ3, although expressed on VSMC, 
contributes only to a very small extent to the inhibiting properties of RV on Akt 
phosphorylation and presumably can be excluded as the main molecular target of RV in 
VSMC. 
 
 
 
FAK, although first discovered just 15 years ago, is a very well studied molecule playing 
important roles in both growth factor- and migration-dependent signalling processes 
[168]. Due to its size and multiple phosphorylation sites, it is a very suitable molecule to 
properly distribute incoming growth factor and integrin signals by interacting with 
different adapter proteins [173]. Since we were not able to determine possible changes 
in the interaction pattern of integrins with FAK (see above) we had a deeper look into 
FAK phosphorylation, which is a crucial parameter of its activity. We first discovered that 
FAK was dephosphorylated when stimulated with EGF for five minutes. Given the fact, 
that EGF stimulation is a rather activating stimulus and FAK phosphorylation is a 
criterion for its activity, it was quite unexpected that total FAK phosphorylation was 
diminished upon stimulation with a mitogen. However, our group was not the only one 
observing such results [271]. It is in fact plausible, that after applying an activating 
stimulus, the cell switches to a more motile phenotype and therefore has to destruct 
focal contacts, which starts with FAK dephosphorylation and subsequent focal complex 
disassembly [271]. Further addition of RV to EGF-stimulated cells completely restored 
the phosphorylation status of FAK, indicating that RV most likely changed parameters in 
the focal complex formation giving us a first indication that RV might act in an anti-
migratory way. FAK dephosphorylation did not change the recruitment of FAK to the 
EGFR, although it has been shown that these molecules are able to interact with each 
other [271, 272].  
 
By stimulating VSMC with a phosphatase inhibitor, we could show that FAK 
dephosphorylation was phosphatase-related and mainly a result of either activation of a 
phosphatase or a prolonged interaction of FAK with a target phosphatase, but probably 
not due to inhibition of a kinase. The phosphatase Shp-2 has been well described to be 
part of the focal adhesion complex and it is known that FAK can be a direct substrate of 
Shp-2 [273, 274]. Enhanced interaction of Shp-2 with FAK was observed also by us 
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when carrying out co-immunoprecipitation experiments, presuming a direct interaction 
between these two proteins. However, we cannot eliminate the possibility that the 
interaction between FAK and Shp-2 is mediated by one or more adapter proteins. It is 
even likely that more proteins are involved given the fact that focal complexes comprise 
of several molecules. The importance of Shp-2 in FAK dephosphorylation was further 
proved when using fibroblasts expressing a truncated and functionally inappropriate 
acting Shp-2 [131]. Both, EGF and RV stimulation in these cells led to a slight induction 
of FAK phosphorylation above basal level, which itself was augmented compared to the 
FAK phosphorylation status in VSMC. Moreover according to the literature [275], 
truncated Shp-2 failed to physically interact with FAK and therefore could not exert its 
phosphatase activity.  
 
Shp-2 has drawn the attention of our group even before, since we speculated that the 
highly redox-regulated phosphatase could be the primary target of the antioxidant RV. 
However, EGF stimulation experiments using a single-methylated derivative of RV (3,5-
dihydroxy-4´-methylstilbene) gained results comparable to those using the hydroxylated 
molecule when determining Akt phosphorylation, although the derivative showed no 
antioxidative capacity (Schreiner Cornelia, PhD thesis 2009). This would mean that RV 
exerts its inhibitory activity not only due to its antioxidant properties, but potentially via 
deregulating protein recruitment processes.  
 
Taken together, our results assume that RV diminishes the interaction of FAK with Shp-
2 and therefore counteracts EGF-mediated FAK dephosphorylation by the 
proteintyrosine phosphatase Shp-2. 
 
 
 
Since the phosphorylation levels of single tyrosine sites within FAK can be regulated 
independently, we wanted to know if the single tyrosine residues are stronger influenced 
by either EGF, RV or both than the total phosphorylation of FAK. Surprisingly, although 
the auto-phosphorylation site Tyr397 was affected in an equal way as the overall 
phosphorylation status of FAK upon EGF stimulation, addition of RV did not restore 
phosphorylation of this particular site to normal levels as expected. Since this residue is 
thought to be a suitable parameter for FAK activity, this would mean that both, EGF 
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alone and in combination with RV diminished the kinase activity of FAK within a short 
incubation time of five minutes. These observations were also made by others using 
either EGF [271] or RV [237] as stimuli, although in both studies cancer cell lines were 
used. It is feasible, that FAK activity is downregulated after EGF-stimulation because of 
the aforementioned actions of focal complex disassembly. It would be interesting to 
investigate EGF- and RV-mediated time kinetics of FAK Tyr397 phosphorylation. It is 
possible that RV keeps Tyr397 phosphorylation reduced for a prolonged time frame, 
which would inhibit FAK activity whereas EGF stimulation would lead only to a short 
Tyr397 dephosphorylation phase which would be restored or even enhanced to reactivate 
FAK for migration. 
 
Other important phosphorylation sites are Tyr576/577, which are phosphorylated by 
members of the Src family [173]. Our observations revealed that these tyrosine residues 
were differently regulated as Tyr397, since EGF with or without RV enhanced the 
phosphorylation of Tyr576/577. Although it is well established that Tyr576 and Tyr577 are 
additional markers for FAK activity, recent data dealing with those residues are rare. In 
most cases, researchers look exclusively at Tyr397 especially when determining the 
activity of FAK. Since phosphorylation of Tyr576/577 within the kinase domain of FAK leads 
to conformational changes which go along with enhanced activity but do not additionally 
represent binding sites for adapter proteins, these results would mean that FAK activity 
is enhanced upon EGF alone or in combination with RV, counteracting previous results 
of diminished Tyr397 phosphorylation. Moreover, it is undisputed that Tyr397 
phosphorylation is followed by binding of Src and subsequent Tyr576/577 phosphorylation 
[172]. We, however, failed to co-immunoprecipitate Src with FAK. One explanation for 
these apparently contradictory results might be the time kinetics of FAK activation. Since 
we stimulated VSMC only for five minutes with EGF, we might have missed the 
hyperphosphorylating phase of Tyr397, which is an important requirement for Src binding 
and subsequent Tyr576/577 phosphorylation. This means, that Y397 phosphorylation and 
binding of Src might have occurred during the first four minutes of EGF stimulation and 
for this reason we were only able to detect Src-mediated Tyr576/577 hyperphosphorylation 
at our five minutes time point. Indeed, it has been already shown by others that Tyr397 
phosphorylation was rapidly induced after two minutes of growth factor stimulation [276]. 
Further time-course experiments would be reasonable to elucidate this possibility. 
Moreover the Src family comprises not only Src, but also Fyn, Yes, Lyn and other 
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members [277]. It is well known that FAK can physically interact with and be 
phosphorylated by different members of the Src family [278], which we were not 
investigating in our studies. 
 
Since phosphorylation of Tyr861 and Tyr925 did not change significantly after five minutes 
of EGF +/- RV stimulation, we could exclude any effects of the two stimuli on adapter 
protein binding to Tyr925 of FAK in this time range. However, the phosphorylation kinetics 
of these two particular tyrosine residues might be different, which has to be taken into 
account. Possible changes in the binding affinities between PI-3K and FAK would have 
been interesting to study, since it was shown that FAK is able to link signalling to Akt via 
contribution of PI-3K [279]. However, we were not able to detect an interaction of FAK 
with PI-3K in our cellular setting. 
 
We might have had also technical problems when carrying out co-immunoprecipitation 
experiments, since we failed to detect several target proteins which should interact with 
FAK. This fact is most likely due to the composition of the lysis buffer, although we made 
several adoptions. Especially salt concentrations play a stringent role when monitoring 
protein-protein interactions, which should be taken into consideration for future 
experiments. Additionally as already mentioned above, we might just have missed the 
right time points after EGF stimulation to detect changes in protein-protein interactions. 
Moreover a putative role of FRNK, the N-terminally deleted negative regulator, has not 
been determined. It was shown, that FRNK is expressed in embryonic rat VSMC at high 
levels [165], but it is still not completely clear how FRNK expression is regulated and 
what the molecular and phenotypic consequences of FRNK overexpression are [191]. It 
is speculated, that FRNK gets expressed when the composition of the ECM changes, for 
example within sites of vascular injury, and it was clearly demonstrated that FRNK 
upregulation led to FAK dephosphorylation [280]. 
 
We could show that rapid dephosphorylation of FAK is due to enhanced interaction with 
Shp-2, but there are still open questions regarding the kinetics of single phosphorylation 
sites of FAK when stimulated with EGF and the role of RV in this context. 
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RV is a well-known antioxidative compound and has been shown to inhibit ROS 
production in many cell systems [281, 282]. In VSMC, RV was reported to diminish 
ROS-dependent DNA damage [226]. ROS are not only produced intracellularly, but are 
also generated in the microenvironment of ligand-bound growth factor receptors. At the 
EGFR, extracellular ROS are generated and act as important second messengers to 
trigger growth factor phosphorylation and facilitate signalling [260, 283]. By using 
Amplex Red™ we wanted to know, if growth factor stimulation can lead to enhanced 
amounts of extracellularly produced H2O2 in VSMC and if RV could reduce them.  
 
Surprisingly, we found that VSMC were producing quite high amounts of extracellular 
H2O2 even when left unstimulated. The measured values were approximately three times 
higher compared to cells treated with catalase used as negative control. Whether these 
high levels were stress-induced due to the handling of the cells (VSMC were transferred 
to another room, washed with PBS and incubated in a special buffer) or if this state 
should be considered as “normal”, cannot be answered at present. However, a recent 
study using VSMC and Amplex Red™ observed comparable high background H2O2 
production [284]. RV was reducing the basal H2O2 levels by 60%. Addition of either Ang 
II or EGF enhanced extracellular H2O2 by 20% in a time-dependent manner, which could 
be also counteracted by pretreatment with RV. These rather low amounts of growth 
factor-induced H2O2, although going along with the results of aforementioned paper 
[284], might be due to limitations of the assay system. One can imagine that generated 
H2O2 which is released to the supernatant might increase vigorously but very locally 
around the receptor but cannot be measured to this extent in the whole supernatant due 
to a dilution effect. The source of generated H2O2 still remains to be determined, 
although Dikalov and colleagues identified NOX1 as the producer of Ang II-mediated 
extracellular H2O2 [284]. EGF-triggered H2O2 production might be the result of receptor-
ligand interaction itself, since DeYulia et al. demonstrated that H2O2 can even be 
generated when using isolated EGFR plus EGF in a cell-free system [260]. Since H2O2 
has been shown to both diffuse through membranes to activate intracellular signals and 
to be able to phosphorylate EGFR [283, 285], it is very likely that a 60% inhibition of 
H2O2 production by RV may cause implications also in intracellular signalling cascades. 
Additional studies in our group revealed, that RV not only affected extracellular but also 
intracellular ROS levels (Schreiner Cornelia, PhD thesis 2009) underlining the very 
potent antioxidative properties of the polyphenol.  
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With these experiments we could verify the potent antioxidant capacity of RV and 
furthermore could show that RV is able to diminish extracellularly produced ROS levels. 
Whether this effect is due to inhibition of H2O2 production at the protein level or via a 
possible scavenger potential of RV, awaits further investigations. 
 
The main goal, to find the specific target of RV which accounts for the inhibiting effects 
of RV on Akt phosphorylation, was unfortunately not reached. We investigated several 
possible target molecules which we found contributing not or only poorly to the effects of 
RV (integrin αVβ3, ERα) and found FAK, which is maybe involved to a bigger extent in 
these processes. Within the scope of this project, other putative molecules could also be 
excluded as the main targets of RV: SIRT and redox-regulation of Shp-2 (Schreiner 
Cornelia, PhD thesis 2009), which leads us to the assumption that one single target 
protein might not exist. The effects of RV can be explained by the fact that multiple 
proteins are involved, which in sum might lead to the vigorous effects of RV. Based on 
this presumption, it is possible that several signalling events upstream of Akt are 
moderately affected by RV, which all end up in decreased Akt phosphorylation. On the 
other hand, the seen effects of RV are very specific for the PI-3K/Akt pathway, since 
previous results of our lab showed no or very little inhibiting properties of RV on other 
signalling pathways [251]. One way to solve this problem would be to carry out affinity 
studies attaching RV to solid phase columns and “fishing” possible target proteins out of 
whole cell lysates. By following mass spectrometry, new putative target proteins could 
be detected which can be followed up in vitro and in vivo.  
 
 
 
RV has been documented to be an anti-invasive molecule in different cancer cell studies 
[237, 238]. VSMC migration is one very crucial step in the early phases of 
atherosclerosis, when cells migrate from their natural surrounding of the media into the 
intima of the vessel [22]. We therefore wanted to investigate, if RV can act as anti-
migratory compound in VSMC, which would make it a putative promising agent for 
counteracting early steps of atherosclerosis. For this purpose, we performed wound 
healing experiments, which is a well-established method for the quantification of 
migration [286]. Beside the wound healing assay, another method to quantify migration 
is the Boyden chamber assay, where a pore-comprising insert is put into a well 
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containing the stimulus of choice. Cells are then seeded into the upper chamber of the 
insert and migration through the pores towards the lower well takes place. Afterwards, 
migrated cells are stained and counted [287]. Supporters of this method highlight, that 
the Boyden chamber assay is more convenient to measure chemotaxis towards a 
gradient and cells have to actively migrate through the small pores. There are, however, 
also disadvantages. Beside the high costs, the stimulus gradient is not maintained for a 
long time, since it distributes throughout the complete volume of medium. 
 
To induce migration, we decided to establish dose-response experiments using 1-100 
ng/ml EGF. We discovered that 20 ng/ml EGF was inducing migration to 50% above 
basal level which could not be enhanced further, even when five times more EGF was 
used. Indeed, it is well known that low concentrations of a growth factor would 
preferentially initiate migration, whereas higher amounts tend to induce proliferation 
[288]. For PDGF, we established migration assays ranging from a concentration of 500 
pg/ml to 10 ng/ml (not shown). In this case we used 2 ng/ml for subsequent experiments, 
since it induced migration robustly (2.5 fold) and was in accordance with other 
publications, where VSMC have been utilized for migration studies either [261]. The 
proliferation cycle of cultured rat VSMC lasts approximately 26-28 hours (Sroka Irene, 
PhD thesis 2009) and since we stimulated our cells for maximal 21 hours, we excluded 
that cell proliferation could perhaps falsify our results of migration induction. Moreover 
we used in preliminary experiments mitomycin C, a potent proliferation blocker [289], to 
obviate proliferation by a second method.  
 
By preincubating VSMC with 50 µM RV, we could clearly show that RV specifically 
affects EGF-, but not PDGF-induced migration (Fig. 21). This effect was not due to the 
usage of different concentrations of growth factors, since very similar patterns of action 
were discovered when using higher amounts of either growth factor, presuming a 
substantial growth factor-specific anti-migratory effect of RV.  
 
Since the molecular basics of migration are very complex, we focussed first on a few 
central key players of cell chemotaxis: FAK and the small GTPases RhoA, cdc42 and 
Rac1. First experiments targeting FAK in a time-kinetics approach revealed that FAK 
was hyperphosphorylated upon EGF stimulation after 8 hours but RV was not able to 
compensate this effect. Given the fact, that activation of small GTPases, especially 
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Rac1 and cdc42, occurs very rapidly [201, 202] and the assumption that FAK would act 
upstream of these molecules, it would be feasible to furthermore look at FAK 
phosphorylation after one to two minutes of growth factor stimulation. Such short 
incubation times are, in fact, not easy to reproduce and results are therefore often 
unstable. It remains therefore elusive if total phosphorylation or phosphorylation of 
certain tyrosine residues within FAK might be affected by very short growth factor 
stimulation times. Furthermore it is until now not fully understood, whether FAK acts 
upstream or downstream of the small GTPases and FAK is also discussed to be even 
not absolutely necessary for activation of small GTPases [203, 204].  
 
Fluorescence-labelled phalloidin is widely used as a molecule to specifically stain actin-
bundles in the cell [290] providing qualitative evidence, which actin structures might be 
affected by a migration-inhibitory stimulus. Phalloidin stainings of EGF-activated VSMC 
revealed, that mainly lamellipodia formation was affected by RV (Fig. 22). We 
furthermore wanted to confirm the microscopically observed changes in the actin 
architecture by more quantitative methods. We therefore conducted pull-down assays 
targeting GTP-bound small GTPases which are accountable for the development of 
specific actin substructures. The time-kinetics of growth factor-induced GTPase-
activation is very cell-type specific and can also vary between the single GTPases. 
Whereas cdc42 and Rac1 get activated within minutes [201, 202, 291], RhoA is often 
shown to bind GTP after 30 to 90 minutes [292, 293], which makes it very tricky 
especially for RhoA to catch the right activation time point.  
 
We could clearly show that impaired lamellipodia-formation is indeed due to inhibition of 
Rac1 in EGF- but not in PDGF-stimulated VSMC after five minutes (Fig. 23). These 
observations go along with the wide accepted model, that Rac1 is mainly responsible for 
the constitution of lamellipodia. Since PDGF-activated Rac1 was not influenced by RV, it 
is not likely that RV acts as a direct Rac1 inhibitor. Interestingly it was shown recently, 
that EGF-mediated Rac1 activation is mediated by the MAPK MEK1, which acted 
directly upstream of Rac1 [294]. Moreover, our group could show that RV was 
significantly inhibiting ERK1/2 phosphorylation in VSMC when using Ang II [251, 295]. 
These data could lead to the assumption, that RV possibly targets the upstream of Rac1 
and ERK 1/2 located kinase MEK1, which awaits further investigation. Another putative 
target of RV might be Dock4, recently identified as specific GEF for Rac1 [296].  
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On the contrary, formation of filopodia was hardly seen microscopically nor did we 
determine any changes in cdc42 activation upon EGF, PDGF or RV stimulation. Since 
the formation of filopodia is one important step in cell migration and has to occur [211], 
we therefore speculate that we did not choose the right time point after growth factor 
stimulation to monitor the development of filopodia. Although we were able to detect 
single filopodia under the microscope, their capillary and needle-like structure made it 
difficult to detect changes in the number per cell or even the structure. At the molecular 
level, cdc42 activity was monitored after two minutes of growth factor stimulation, which 
was in accordance with other publications [202, 297]. Initial experiments revealed, that a 
slight but not significant activation of cdc42 (15% above basal level) could be monitored 
after two minutes. This effect, however, was very unstable and not reproducible. 
Moreover Czuchra and colleagues could observe that cdc42 is not essential for filopodia 
formation, since cdc42-deficient fibroblasts did not show significant changes in migration 
speed or filopodia number per cell and therefore speculated that other members of the 
Rho family could compensate for the loss of cdc42 [298]. Indeed, another study 
revealed Rho in filopodia (RIF) as a novel and important protein involved in filopodia 
formation [299]. Furthermore, technical issues might have played a role that we did not 
have the ability to determine changes in cdc42 activity. PAK Agarose beads comprise a 
small amino acid sequence of PAK, a direct downstream target of both Rac1 and cdc42, 
which means that both GTPases are able to bind to the beads. Rac1 amounts in VSMC 
are quite high, and therefore active Rac1 could rapidly occupy the beads-attached PAK 
recognition sites which might have the consequence that weakly expressed cdc42 has 
no chance to bind.  
 
The third member of small GTPases we were interested in was RhoA, a protein strongly 
involved in stress fibre formation. Microscopically, we could clearly observe the 
development of stress fibres after stimulation with either EGF or PDGF for one to four 
hours. Additional treatment with RV, however, had apparently no effects on the 
generation of stress fibres visualized by phalloidin-FITC. Unfortunately, pull-down 
assays targeting activated RhoA did not work at all, which was most likely due to non-
binding of VSMC RhoA to the beads-linked binding site. For positive control, we loaded 
1 mg of lysate with GTP to gain high amounts of GTP-bound RhoA. Even with this high 
GTP-RhoA-containing lysate, we were not successful to immunoprecipitate RhoA, which 
prompts us to speculate that rat RhoA was not binding to the beads supplied by the 
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company. Furthermore, the possible wide time-frame of RhoA activation could still be a 
problem in future approaches to effectively precipitate active RhoA. One possibility to 
circumvent these technical problems is to apply another and more sensitive method, like 
approaches which are based on changes in the emission wave length when the 
substrate is been converted.  
 
Taken together, we could highlight a stimulus-specific anti-migratory action of RV in 
VSMC, which is mainly a result of impaired Rac1 activation followed by reduced 
lamellipodia development. 
 
 
 
All experiments in this study were conducted using 50 µM of RV. This is a quite high 
concentration when compared to the maximal in vivo levels which can be achieved in 
target tissues of humans either drinking red wine or eating RV-containing tablets [300]. 
In addition, it has been clearly shown that blood half-life of RV is short and that RV 
metabolites occur in plasma and urine. It is still not fully understood if certain metabolites 
of RV possess equal or even higher activity as unmetabolized RV [301, 302]. In some 
experiments, we tried to investigate the role of integrins as potential receptors for RV. 
Until now, it is completely unknown if RV can act via receptor binding or not. Due to its 
structure, RV is able to pass the cell membrane without the need of transport proteins, 
which has been shown to occur in vitro [303] and is also likely in vivo. However, some of 
the effects exerted by RV are still explainable via a direct receptor interaction. Moreover, 
biodistribution of RV and its shuttling to tissues remain open questions. It has been 
shown that 18F-labelled RV was predominantly found to be enriched in liver and kidneys 
of rats, and was excreted rapidly and to a high extent [304]. Since we tried to unravel 
possible new molecular targets of RV in a mechanistic in vitro study it is, as part of the 
fundamental research, plausible to use 50 µM RV as a tool to find new molecular targets 
to fight cell hypertrophy and which might provide insight into the molecular actions of the 
polyphenol. Moreover, this study is based on previous results gained in our lab using 50 
µM RV and therefore it was feasible not to change the experimental setting when 
continuing to search for the molecular targets of RV in VSMC.  
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Isolated VSMC from rat aortas were used in this study to mimic the in vivo situation 
within atherosclerotic lesions. It should be taken into account that VSMC grown in vitro, 
definitely react differently as VSMC embedded in the arterial wall or the atherosclerotic 
lesion. The multiple interactions which take place between VSMC and ECM or VSMC 
and cells of other tissues cannot be imitated in vitro, where they are grown in Petri-
dishes and without co-cultivation of other cell types. Results from such in vitro-based 
approaches should therefore always be confirmed in vivo as well, since several studies 
highlighted evident differences between these two models [305]. One good example is 
the fact, that mature contractile VSMC isolated from the media of animals and grown in 
cell culture undergo a “phenotype switch” and gain characteristics of intimal VSMC [306]. 
Our in vitro cell culture model is therefore an appropriate tool to study dedifferentiated, 
non-contractile VSMC in an activated manner similar to intima-invading VSMC in vivo. 
However, by comparing the gene expression profile of freshly isolated medial VSMC 
and cultivated late-passage VSMC, Shanahan and colleagues found 12 markers 
differentially expressed mainly involving proteins of the cytoskeleton network and ECM 
[307]. In vitro research is nevertheless a cruical requirement to elucidate mechanistic 
principles for successive investigations in vivo. 
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G  Appendix 
 
 
 
1.  Abbrevations 
 
A 
ACE  angiotensin converting enzyme 
ADAM  a disintegrin and metalloproteinase 
Ang I  angiotensin I 
Ang II  angiotensin II 
AP-1  activator protein-1 
AR  amphiregulin 
ARP 2/3 actin-related protein 2/3 
AT-1R  Ang II-type 1 receptor 
 
B 
bFGF  basic fibroblast growth factor 
BSA  bovine serum albumine 
BTC  betacellulin 
 
C 
Cas  Crk-associated substrate 
CB  cytoskeleton buffer 
CD  cluster of differentiation 
CDK  cyclin-dependent kinase 
CE  cytoplasmatic extract 
CHD  coronary heart disease 
COX  cyclooxygenase 
CR  caloric restriction 
CREB  cAMP response element-binding protein 
Crk  CT10 sarcoma oncogene cellular homologue 
CVD  cardiovascular disease 
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D 
DAG  1,2-diacylglycerol 
DMSO  dimethylsulfoxide 
 
E 
EC  endothelial cell 
ECM  extracellular matrix 
EGF  epidermal growth factor 
EGFR  EGF receptor 
eNOS  endothelial nitric oxide synthase 
EPR  epiregulin 
ER  estrogen receptor 
ERK  extracellular signal-regulated kinase 
 
F 
FACS  fluorescence-activated cell sorting 
F-actin  filamentous actin 
FAK  focal adhesion kinase 
FAT  focal adhesion targeting 
FERM  protein 4.1, ezrin, radixin and moesin homology 
FIP200 FAK-inhibitory protein 200 kDa 
FGF  fibroblast growth factor 
FRNK  FAK-related non-kinase 
Fvstr  fulvestrant 
 
G 
Gab-1  GRB2-associated binder-1 
GAP  GTPase activating protein 
GDI  guanine dissociation inhibitor 
GEF  guanine nucleotide exchange factor 
GPCR  G protein-coupled receptor 
GRAF  GTPase regulator associated with FAK 
GRB2  growth factor receptor-bound protein 
GRK  G protein receptor kinases 
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H 
HB-EGF heparin-binding EGF-like growth factor 
HIF-1  hypoxia-inducible factor-1 
HDL  high density lipoprotein 
HRP  horseradish peroxidase 
 
I 
ICAM-1 intercellular adhesion molecule-1 
IFNγ  interferon gamma 
IGF  insulin-like growth factor 
IL  Interleukin 
ILK  integrin-linked kinase 
Iκ-B  inhibitor of NF-κB 
iNOS  inducible nitric oxide synthase 
IP3  1,3,5-trisphosphate 
 
K 
KRPG  Krebs-Ringer glucose buffer 
 
L 
LDL  low density lipoprotein 
LMW-PTP low molecular weight tyrosine phosphatase 
LRP6  LDL receptor-related protein 6 
 
M 
MAPK  mitogen-activated protein kinase 
MCP-1  monocyte chemoattractant protein-1  
M-CSF macrophage-stimulating growth factor 
MEK  MAPK/ERK kinase 
MIDAS metal ion-dependent adhesion site 
MLCK  myosin light chain kinase 
MLCP  myosin light chain phosphatase 
MMP  matrix metalloproteinase 
MTOC  microtubule organizing centre 
APPENDIX 
120 
mTOR  mammalian target of rapamycin 
mTORC mTOR complex 
 
N 
NE  nuclear extract 
NF-κB  nuclear factor kappa B 
NOX  NAD(P)H oxidase 
NRG  neuregulin 
 
P 
p130Cas p130 Crk-associated substrate 
PA  phosphatidic acid 
PAK  p21-activated kinase 
PDGF  platelet-derived growth factor 
PDGFR PDGF receptor 
PDK1  3-phosphoinositide-dependent protein kinase 1 
PH  pleckstrin homology 
PI-3K  phosphoinositide-3 kinase 
PIP2  phosphatidylinositol 4,5-bisphosphate 
PIP3  phosphatidylinositol 3,4,5-trisphosphate 
PLCγ  phospholipase C gamma 
PLD  phospholipase D 
PKC  protein kinase C 
PMN  polymorphonuclear cell 
PRNK  PYK2-related non-kinase 
PTP  protein tyrosine phosphatase 
PYK2  proline-rich tyrosine kinase 2 
 
R 
RAS  renin-angiotensin system 
RGD  arginine–glycine–aspartic acid (Arg-Gly-Asp) 
RIF  Rho in filopodia 
ROCK 1/2 Rho-associated coiled-coil-containing protein kinase 1/2 
ROS  reactive oxygen species 
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RTK  receptor tyrosine kinase 
RV  resveratrol 
 
S 
S1P  sphingosine-1 phosphate 
SH2  src homology 2 
Shc  SH2-containing collagen-related protein 
Shp-1  SH2-containing phosphatase 1 
Shp-2  SH2-containing phosphatase 2 
SIRT1  sirtuin 1 
SM-MHC smooth muscle myosin heavy chain 
SOS  son of sevenless 
Src  Rous sarcoma oncogene cellular homolog 
STAT  signal transducer and activator of transcription 
 
T 
TGF-α/β transforming growth factor alpha/beta 
TLR  toll-like receptor 
TNF α/β tumour necrosis factor alpha/beta 
 
V 
VCAM-1 vascular cell adhesion molecule-1 
VSMC  vascular smooth muscle cell 
 
W 
WASP  Wiskott-Aldrich syndrome protein 
WAVE  WASP family verprolin-homologous protein 
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2.1. Publications 
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